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Cancer cells undergo metabolism that is significantly different to normal cells, with an 
increased dependence on glucose metabolism as a hallmark of most cancers. Changes in 
global gene expression patterns are the major driving forces behind cancer progression. These 
changes trigger events that result in the dysregulation of key enzymes associated with 
metabolic processes. Gene expression profiling studies done previously in our laboratory 
identified a group of genes involved in glucose metabolism to be differentially expressed in 
cervical cancer patient material. Of these, Phosphoglucomutase 1 (PGM1) was identified to 
have elevated expression in the cancer group. PGM1 is a phosphotransferase that catalyses 
the reversible conversion of the glycogen breakdown product, glucose-1-phosphate into 
glucose-6-phosphate, a substrate for glycolysis and the pentose phosphate pathway. This 
places PGM1 at a critical traffic point of glucose metabolism. In this study we investigated the 
expression, regulation and biological significance of PGM1 in cancer cells. Our results showed 
that PGM1 expression was elevated in cervical cancer tissue compared to normal. Its 
expression was also high in cervical, oesophageal and breast cancer cell lines. Elevated PGM1 
expression associated with high promoter activity as well as with E2F and HIF1α activities in 
cancer cells. PGM1 expression at the level of mRNA, protein and promoter activation was 
significantly stimulated in hypoxia mimicking conditions. Our data showed that PGM1 
expression in cancer cells was required mainly for glycogen accumulation with marginal 
changes on glycolysis and the pentose phosphate pathway. While PGM1 expression did not 
appear necessary for cancer cell proliferation in normoxia and nutrient sufficiency, our data 
shows that it is required for proliferation under conditions of glucose deprivation combined 
with hypoxia. Together these findings suggest that PGM1 expression is altered in cancer cells, 
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that it is required for aberrant glycogen expression in cancer cells and that it has a role in 






1.1 Global cancer burden 
“The diseases that are grouped together as cancers are among the major liabilities to human 
life.” This was an opening line in a recent commentary addressing leaders in cancer research 
and policy from 15 economically diverse countries meeting to discuss opportunities to reduce 
cancer incidence and mortality. The main aims were to improve cancer care, and increase 
current understanding of disease pathophysiology, thereby enabling faster progress in 
confronting the growing challenge of cancer worldwide (Varmus & Kumar 2013).   
The World Health Organization published in 2008, that cancer is the leading cause of death in 
economically developed countries and the second leading cause of death in developing 
countries (World Health Organization 2008).  According to Jemal and co-workers (2011) the 
burden of cancer is emergent in economically developing countries as a result of population 
aging and growth (Edwards et al. 2002) as well as, increasingly, an adoption of cancer-
associated lifestyle choices including smoking, physical inactivity, and ‘‘westernized’’ diets 
(Jemal et al. 2011; Hanahan 2014). Globally, there are about 12.7 million newly diagnosed 
cancer cases per year and a reported 7.6 million cancer deaths are estimated to have occurred 
in 2008; of these, 64% occurred in the economically developing world (Jemal et al. 2011; 
Varmus & Kumar 2013). Cancer in the developing world thus poses a major health risk which 
is exacerbated by poorer cancer survival in developing countries, most likely due to a 
combination of a late stage diagnosis and limited access to timely and standard treatment 
approaches (Lingwood et al. 2008; Jemal et al. 2011). New drugs and treatment regimens and 
modern technologies are generally unaffordable or logistically impractical to deliver to 
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patients (Hanahan 2014). As such, the search for new diagnostic tools and therapeutic 
strategies against cancer continues. Our research in the field is directed towards obtaining a 
better understanding of the molecular mechanisms that underpin cancer development with 
the hope to discover of novel cancer biomarkers and therapeutic targets.  
 
1.2 Therapeutic targeting of cancer hallmarks  
Cancer is a complex disease involving numerous tempo-spatial changes in cell physiology, 
which ultimately lead to malignant tumours. The consequent abnormal cell growth (or 
neoplasia) is the biological endpoint of the disease (Seyfried & Shelton 2010). Transformation 
of normal human cells into malignant cancers is preceded by the progressive acquisition of 
specific characteristics which become definitive of the cancer phenotype, and these 
characteristics are collectively termed ‘cancer hallmarks’ (Hanahan et al. 2000). ‘Hallmarks’ 
constitute an organizing principle for rationalizing the complexities of neoplastic disease 
(Hanahan & Weinberg 2011). From an initial six capabilities, described by Hanahan and 
Weinberg (2011), research in the last decade has advanced to the adoption of the following 
ten cancer hallmarks: 1) sustained proliferative signals 2) evasion of growth suppressors 3) 
avoidance of immune destruction 4) replicative immortality 5) enabling of tumour promoting 
inflammation 6) activation of invasion and metastasis 7) induction of angiogenesis 8) 
allowance of genomic instability and mutation 9) resistance of cell death and 10) deregulated 
cellular energetics Figure 1.1 (Hanahan & Weinberg 2011). These cancer hallmarks form a 
molecular signature of cancer cells that differentiates them from normal cells and therefore 
offers the selectivity necessary for target discovery. Research efforts have investigated the 
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targeting of these different cancer capabilities as distinct therapeutic approaches. and Figure 
1.1 shows illustrative examples of candidate drugs against the specified molecular targets. 
 
 
Figure 1.1. Therapeutic targeting of the hallmarks of cancer 
Drugs that interfere with each of the acquired capabilities necessary for tumour growth and 
progression have been developed and are in clinical trials or in some cases approved for 
clinical use in treating certain forms of human cancer. Additionally, the investigational drugs 
are being developed to target each of the enabling characteristics and emerging hallmarks 
which also hold promise as cancer therapeutics. From (Hanahan & Weinberg 2011) 
 
The investigation of gene expression patterns across cancer cohorts typically directs the 
search for novel potential targets and often reveals a contextual profile of genomic and 
epigenetic changes that underlay the tumourigenic landscape of any particular cancer. 
Studies have shown that certain cancers demonstrate specific hallmark changes that provide 
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an opportunity for targeted therapy. For example, some breast cancers show an 
overexpression of the human epidermal growth factor receptor (HER2) and as such, tyrosine 
kinase inhibitors have been used to selectively target these malignant cancer cells, the drug 
Herceptin (trastuzumab) being one such example (Vogel et al. 2003). 
The discovery of drugs such as Gleevac (Imatinib) certainly speaks to the promise of the 
‘silver/magic bullet’ approach to finding new and effective cancer therapies with reduced 
toxicity towards normal cells and reduced side effects that often follow off-target drug 
binding. In this specific example, much success was seen, in which genomic instability was 
targeted through the design of an inhibitor specific to the BCR-ABL tyrosine kinase, a fusion 
protein that results from a reciprocal translocation between chromosome 9 and 22q, and is 
responsible for the onset of chronic myelogenous leukaemia (CML). CML patients treated 
with Gleevac, had an estimated overall survival rate in a 5-year follow-up trial of 89%, with a 
relapse rate of only about 17%, compared to an initial 30% patient survival rate following prior 
traditional treatment protocols which were also expensive (Druker et al. 2006; Pray 2008). 
This is a success story, however, an exceptional case as unlike most other cancers, which are 
caused by a multitude of complex interacting genetic and environmental factors (and 
therefore involving multiple targets), CML is caused by a single aberrant protein related to a 
consistent chromosomal translocation (Pray 2008).  
Although a growing number of inhibitors that target specific components of the altered 
cancer capabilities are in clinical use, the success  and efficacy of these agents has been limited 
by resistance to inhibitor therapy (Logue & Morrison 2012; Locasale 2012). Detailed 
bioinformatic analyses have suggested that cancer-related driver mutations affect a dozen or 
more core signalling pathways and processes responsible for tumourigenesis, leading to 
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questions about the usefulness of targeting individual signalling molecules as a practical 
therapeutic strategy. This singular approach towards treatment does not cater for cancer’s 
ability to adapt signalling circuitry, which enables cancer cells to take advantage of pathway 
redundancy and routes of feedback and cross-talk in order to sustain their progression (Cairns 
et al. 2011; Logue & Morrison 2012). The challenge of better understanding of carcinogenesis 
therefore still remains. 
 
1.3 The Tumour Microenvironment  
“Tumours are complex tissues in which mutant cancer cells have conscripted and subverted 
normal cell types to serve as active collaborators in their neoplastic agenda” (Hanahan et al. 
2000). The tumour microenvironment  describes the local conditions experienced by cells in 
a tumour, including the levels of nutrients, oxygen and signalling molecules such as growth 
factors and cytokines (Vander Heiden 2011). The interactions between these 1) local 
conditions, 2) genetically altered neoplastic cells and 3) ‘normal’ supporting cells around solid 
tumours are proving to be all critical to understanding cancer pathogenesis and have 
implications on the development of novel, effective therapies. A good example to illustrate 
this, is in a study conducted by Smith and co-workers (Smith et al. 2013). Their data showed 
that tumours assume a differential architecture that either makes them resistant or 
susceptible to anti-angiogenic treatment in this case, VEGF inhibition. In this study, xenograft 
tumour cells that displayed a ‘stromal-vessel’ (SV) phenotype appeared somewhat resistant 
to the VEGFR2 inhibitor, DC101 (a monoclonal neutralizing antibody); SV-type tumours being 
characterized by a dominant pattern of tumour cell nests surrounded by well-developed 
stromal structures containing the majority of the vessels. Their study showed that in contrast 
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to tumours of the SV-type architecture, the ‘tumour-vessel’ (TV) phenotype, in which the 
tumour structure showed vessels embedded throughout the tumour cell mass, showed 
greater sensitivity to this anti-angiogenic treatment in vivo (Smith et al. 2013). Their 
observations highlight the importance of considering the contribution of the supporting 
cellular compartment in and around cancer cells in evaluating and developing a holistic 
understanding of carcinogenesis, the tumour microenvironment and consequent implications 
upon treatment approaches. The stromal architecture may influence the intrinsic metabolic 
status of the tumour cells either directly, or by creating a dependency on metabolic coupling 
between the stromal fibroblast and tumour to promote anabolic growth (Whitaker-Menezes 
et al. 2011). 
The cellular compartment of the tumour microenvironment is comprised of neoplastic cancer 
cells that initiate the creation of the tumour niche, and cells that maintain the structural 
framework of tumour tissue. These tumour cells are a collective grouping of mesenchyme-
derived cells called cancer-associated fibroblasts (CAFs) recruited from local tissues to the 
tumour site (Polanska & Orimo 2013). CAFs differ from normal fibroblasts in that they display 
increased proliferation, enhanced extracellular matrix production and a unique cytokine 
secretion profile (e.g. VEGF, Stromal cell-derived factor 1; SDF1, platelet derived growth 
factor (PDGF) and others) (Polanska & Orimo 2013; Junttila & de Sauvage 2013). Maintenance 
of cells requires tumour vasculature composed of endothelial cells and pericytes which 
assume a diverse morphology compared to the normal vasculature. The host vessels provide 
the structure from which new blood vessels are formed. The ability to recruit de novo formed 
vessels not only supplies oxygen and nutrients for the growing tumour mass (Fiaschi & 
Chiarugi 2012) but allows for the infiltration of immune cells. Both the innate and adaptive 
immune systems have been implicated in promoting and preventing tumour growth. 
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Although the immune system has the ability to mount anti-tumour responses, mechanisms 
of immune suppression can prevent this process (Junttila & de Sauvage 2013). Figure 1.2 
shows a comprehensive overview of the cellular compartment of the tumour 
microenvironment and the functions of the individual players in propagating and maintaining 
cancer proliferation and survival.  
 
Figure 1.2. Multiple stromal cell types and sub-cell types of the tumour microenvironment 
can variably contribute to, or in some cases oppose, acquisition of hallmark functional 
capabilities in different organ sites, tumour types and subtypes, and stages of progression. 
Major stromal cell subtypes are indicated, along with a synopsis of key functional 
contributions that such cell subtypes can make. The antagonistic functions of certain subcell 
types are highlighted in gray. The lists of subtypes and of their key functions are not 
comprehensive, but rather prominent examples. Th2, helper type 2; CD4 T cell, CD4-positive 
lymphocyte; Treg, regulatory T cell; CTL, cytotoxic T lymphocyte; NK/T, natural killer and 
natural killer T cell; MDSCs, myeloid-derived suppressor cells; αSMA, alpha smooth muscle 




In order to adequately delineate the local conditions within the tumour microenvironment, it 
is important to consider that cancer cells are typified by deregulated cellular energetics 
(Hanahan & Weinberg 2011) or metabolic reprogramming (Ward & Thompson 2012). The 
altered metabolic profile of tumours occurs in the context of the previously mentioned 
physical and morphological features of the tumour microenvironment which often include 
hypoxia, hypoglycemia and acidity, all of which contribute to tumour pathogenesis (Estrella 
et al. 2013). Reprogrammed metabolic pathways have been the basis behind the design of 
imaging techniques such as positron emission tomography (PET) with F-18 
fluorodeoxyglucose (FDG) (Som et al. 1980; Rohren et al. 2004; Xue et al. 2006; Upadhyay et 
al. 2013). FDG-PET is a technique that exploits the tumour’s affinity for glucose as a means to 
locate and aid in the diagnosis and staging of cancer. A detailed overview of the molecular 
mechanisms and metabolic pathways that underpin the local conditions of the tumour 











1.4 Reprogramming of metabolism in cancer 
Metabolism can be described simplistically as a combination of biochemical processes that 
occur in living things for the maintenance of life. These processes have been categorized into 
two main branches; anabolic metabolism, which refers to the building up of biosynthetic 
molecules and catabolic metabolism, which refers to the breaking down or utilization of the 
molecules imported from the extracellular environment or internally synthesized 
macromolecules. Both anabolic and catabolic processes in cancer cells differ from those of 
normal cells  (Zhao et al. 2013). Cell proliferation requires nutrients, energy, and biosynthetic 
activity to duplicate all macromolecular components during each passage through the cell 
cycle, therefore it is not surprising that metabolic activities of highly proliferating cancer cells 
would be appear different from those in normal cells (DeBerardinis et al. 2008). 
Multiple molecular mechanisms, both intrinsic and extrinsic, converge in cancer  to alter core 
cellular metabolism and provide support for the three basic needs of dividing cells: rapid ATP 
generation to maintain energy status; increased biosynthesis of macromolecules to support 
cellular replication; and maintenance of appropriate cellular redox status for survival (Cairns 
et al. 2011).   
Cancer’s adaptations to meet these needs was first investigated by Otto Warburg. He 
observed a shift in ATP generation from oxidative phosphorylation to glycolysis, even under 
normal oxygen concentrations (Warburg 1956). While Warburg interpreted dependency on 
glycolysis as a function of mitochondrial impairment (Warburg 1956; Carew & Huang 2002), 
this deduction was found to be controversial as more recent evidence has shown that 
mitochondria in cancer cells are both functional and re-programmed to support 
carcinogenesis (Grupp et al. 2013; Moreno-Sánchez et al. 2007). Most cancers readily take up 
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and use glucose as an immediate energy source through accelerated glycolysis (Sonveaux et 
al. 2012; Marín-Hernández et al. 2011; Bao et al. 2013).  
To fuel metabolic requirements of the cell and to supply biosynthetic precursors 
(DeBerardinis et al. 2008), glutamine, one of the most abundant amino-acids is also thought 
to be processed through the mitochondria. Glutamine participates in metabolism as a 
nitrogen and carbon source for biosynthesis (Wise & Thompson 2010) and it has more 
recently  been described as a part of the cancer cell’s acid management system (Huang et al. 
2013). The high rate of glycolysis allows cells to maintain biosynthetic fluxes during rapid 
proliferation but results in a high rate of lactate production which contributes in part to the 
consequent acidity in the tumour microenvironment (DeBerardinis et al. 2008).  
The following section describes the above metabolic alterations, in particular glucose 
metabolism, in more detail to allow for a clearer understanding of the tumour landscape, as 
it relates to our current study. 
 
1.4.1 Glycolysis and lactate metabolism  
The role for glycolysis in normal cells is to synthesize of two molecules of pyruvate, two 
molecules of NADH, and a net production of two molecules of ATP. The pyruvate and NADH 
molecules are then transported to the mitochondria to be further processed for a greater ATP 
yield through aerobic respiration. Pyruvate is cycled through Tri-Carboxylic Acid (TCA) cycle 
for the synthesis of more high energy electron carriers, NADH and FADH2, which together with 
the NADH molecules produced through glycolysis participate via the electron transport chain 
(oxidative phosphorylation) to yield thirty eight ATP per glucose molecule.    
11 
 
In most cancer cells, however, glycolysis and oxygen dependant mitochondrial respiration are 
uncoupled processes. This means that instead of the pyruvate (the glycolytic end product) 
being processed via the TCA cycle, it is instead converted into lactate by lactate 
dehydrogenases (LDH). The lactate is excreted into extracellular matrix. This is similar to what 
happens in normal cells in the absence of oxygen by a process of fermentative glycolysis. 
However this phenomenon occurs in cancers irrespective of oxygen availability, giving rise to 
the generally accepted ‘cancer signature’ termed the “Warburg effect” as Warburg was the 
first to describe this observation.  
The Warburg effect yields a low net output of ATP per glucose molecule compared to that of 
oxidative phosphorylation and much debate and studies have been conducted to elucidate 
why cancer cells rely on uncoupled ‘aerobic glycolysis’. One of the reasons suggested is that 
although the yield of ATP per glucose consumed is low, if the glycolytic flux is high enough, 
the percentage of cellular ATP produced from glycolysis can exceed that produced from 
oxidative phosphorylation (Pfeiffer et al. 2001; DeBerardinis et al. 2008). Therefore ATP 
production via glycolysis can outpace that of oxidative phosphorylation offering an advantage 
to cancer cells. In addition, the expression of glucose transporter, GLUT1  is often increased 
in cancers and conditions such as hypoxia in the tumour microenvironment activate and allow 
for the translocation of glucose transporters to the plasma membrane (Avril 2004), which 
augments the influx of glucose into cells, supporting the high glycolytic rate in these cells. 
Furthermore, glucose degradation via glycolysis provides cells with intermediates needed for 
biosynthetic pathways, including ribose sugars for nucleotides; glycerol and citrate for lipids; 
nonessential amino acids; and, through the oxidative pentose phosphate pathway, NADPH 
(DeBerardinis et al. 2008).  
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Lactate production and excretion by cancer cells as a result of the disconnection of glycolysis 
to mitochondrial respiration was initially thought to be a wasteful consequence of inefficient 
fermentative glucose metabolism. However several studies suggest that lactate secretion by 
cancer cells is not a random event. The emphasis upon cancer cell’s increased glycolytic rate 
has unfortunately led to the idea that cancer cells subsist upon glucose alone with lactate 
being overlooked as a potential fuel, but instead identified only as an acidic promoter of 
metastasis (Nakajima & Van Houten 2013). Another layer of complexity in mapping tumour 
metabolism is added to classic understanding of the Warburg effect by the consideration of 
lactate as a metabolic fuel. Sonveaux et al. (2008) propose a model  of ‘metabolic symbiosis’ 
amongst cells within the context of larger advanced-stage tumour environments and provide 
interesting interpretations on the function of different players in lactate metabolism. This 
idea reviewed by (Semenza 2008) and depicted in Figure 1.3 showing the lactate 
dehydrogenase enzymes and the lactate transporters monocarboxylate transporter (MCT) 1 
and 4. When tumours outgrow their supporting vasculature, areas in the tumour mass that 
are less oxygenated emerge, giving rise to a heterogeneous metabolic profile in cells of the 
same tumour (Sonveaux et al. 2008), adapted specifically to their unique setting. The different 
cells in tumours harbour different properties or metabolic profiles that result from adaptive 
signalling in response to continued exposure to hypoxic environmental stress (Curry et al. 




Figure 1.3. Intratumoral hypoxia and metabolic symbiosis. Tumours are characterized by 
gradients of O2 levels, based on the distance of tumour cells from a functional blood vessel. 
Tumour cells surrounding the blood vessel are well oxygenated, whereas those more distant 
are poorly oxygenated and express high levels of HIF-1. HIF-1 induces the expression of 
proteins that increase: uptake of glucose (e.g., glucose transporter 1 [GLUT1]); conversion of 
glucose to pyruvate (e.g., glycolytic enzymes); generation of lactate and H+ (e.g., LDHA); and 
efflux of these molecules out of the cell (e.g., carbonic anhydrase IX [CA9], sodium-hydrogen 
exchanger 1 [NHE1], MCT4). Two moles of lactate are produced for each mole of glucose 
consumed by the hypoxic cell. This increase in glycolytic metabolism is associated with 
reduced substrate delivery to the mitochondria (through the action of pyruvate 
dehydrogenase kinase 1, PDK1) and reduced mitochondrial mass (as a result of autophagy 
triggered by BNIP3). Aerobic tumour cells express proteins that allow them to take up lactate 
(e.g., MCT1) and use it (e.g., Lactate dehydrogenase B), in the presence of O2, as their 
principal substrate for mitochondrial oxidative phosphorylation. From (Semenza 2013) 
 
The idea of metabolic symbiosis between hypoxic and aerobic tumour cells is illustrated in 
Figure 1.3, where  hypoxic tumour cells primarily use glucose for glycolytic energy production 
and release lactic acid, creating a lactate gradient that is in parallel with the oxygen gradient 
within the tumour (Sonveaux et al. 2008; Semenza 2008; Feron 2009). By contrast, in 
oxygenated tumour cells, lactate becomes the prominent substrate that fuels the oxidative 
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metabolism in these aerobic cells.  This gives rise to symbiosis in which glycolytic and oxidative 
tumour cells mutually regulate their access to energy metabolites (Sonveaux et al. 2008; 
Semenza 2008; Feron 2009; Whitaker-Menezes et al. 2011; Curry et al. 2013).  
 
Metabolic symbiosis is somewhat a controversial idea as it provides an alternative 
interpretation of Warburg’s observation by considering the heterogeneity of tumours. The 
Warburg effect, as it is traditionally reflected and interpreted, does not account for the 
metabolic diversity that has been observed amongst cancer cells within a tumour, nor the 
influences that might direct such diversity (Nakajima & Van Houten 2013). Modern tools have 
shown that oncogenes, variable hypoxia levels, and the utilization of different carbon sources 
affect tumour evolution, while a more orthodox view on the Warburg effect points towards 
cancer cells displaying a single metabolic phenotype, which as discussed earlier is summed up 
as  ‘aerobic glycolysis’. The metabolic symbiosis concept makes a compelling case for another 
way of looking at tumour metabolism by considering the role of lactate and other metabolites 
in the tumour microenvironment, thereby suggesting that cells within the tumour may display 
diverse metabolic profiles.  
1.4.2 Glycogen metabolism 
 Glycogen is a readily mobilized storage form of glucose. It is a very large, branched polymer 
of glucose residues (Figure 1.5) that can be broken down to yield glucose molecules when 
energy is needed. Most of the glucose residues in glycogen are linked by α-1,4-glycosidic 
bonds. Branches that occur at about every tenth residue are created by α-1,6-glycosidic bonds 





Figure 1.5. Structure of glycogen 
The diagram shows of two outer branches of a glycogen molecule, the residues at the non-
reducing ends are shown in pink and residue that starts a branch is shown in green. The rest 
of the glycogen molecule is represented by R. From (Berg et al. 2002) 
 
The general physiological role of glycogen is to serve as a buffer for the maintenance of blood 
glucose levels. Glucose from glycogen is readily mobilized and thereby serves as a source of 
energy for sudden, strenuous activity. Unlike energy stored in fatty acids, the glucose released 
from glycogen can provide energy in the absence of oxygen and hence would be an ideal 
source during anaerobic conditions (Berg et al. 2002). The storage of glycogen is generally 
tissue specific, being isolated to liver, skeletal muscle tissue and brain tissue (Brown & 
Ransom 2007; Obel et al. 2012). Rousset and co-workers investigated glycogen storage in a 
panel of fifty eight human cancer cell lines and detected varying levels in a large majority of 
these cells (Rousset et al. 1981). While this discovery was made a while ago, only recently did 
the significance of glycogen accumulation in cancer cells become a subject for investigation.  
Figure 1.6 depicts the key enzymes, substrates and regulatory components involved in 
glycogen breakdown and synthesis. Synthesis and breakdown of glycogen involves the activity 
of several enzymes and regulatory proteins. Among these, glycogen synthase (GS) and 
glycogen phosphorylase (GP) catalyse the key steps of synthesis and degradation, respectively 




Figure 1.6. Schematic illustration of pathways in glycogen metabolism, in blue boxes; the 
enzymes involved in each reaction (represented as the black arrows) and the substrates, co-
factors and products; in black writing. The main regulatory points for glycogen synthesis and 
breakdown are at the enzymes, glycogen synthase and glycogen phosphorylase respectively 
which are regulated by hormones; Insulin (which activates the synthesis of the glycogen 
macromolecule) and Glucagon and Epinephrine which stimulate the release of the glycogen 
stores in the form of glucose-1-phosphate (G1P) which gets converted to glucose-6-
phosphate (G6P) by the action of Phosphoglucomutase 1 (PGM1). The G6P can then be 
channelled into the glycolytic pathway or pentose phosphate pathway or converted into 
glucose for gluconeogenesis in gluconeogenic tissues by the action of glucose-6-phosphatase.    
 
The role of glycogen in cancer has been studied particularly as it relates to hypoxic tumour 
environments. Recent studies have shown that glycogen accumulation occurs in response to 
tumour stress environments such as treatment with anti-angiogenic therapies such as 
bevacizumab (a VEGF inhibitor that’s routinely administered in the clinic to cut off tumour 
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blood supply and results in significantly reduced oxygen delivery to the tumour site), as well 
as exposure to hypoxia (Favaro et al. 2012; Pescador et al. 2010; Pelletier et al. 2012). Hypoxia 
leads to the overexpression of key enzymes that are involved in glycogen metabolism, 
promoting storage upon prolonged exposure. The detail regarding these mechanisms behind 
glycogen regulation as it relates to the cancer setting will be discussed further in Chapter 4.  
 
1.4.3 The pentose phosphate pathway  
Upon entry into cells, glucose is phosphorylated to form glucose-6-phosphate (G6P) by 
hexokinases. G6P then becomes a substrate for glycolysis, glycogen synthesis as well as the 
pentose-phosphate pathway (PPP). The PPP is essential for cancer cell survival because 
through a series of reactions in this pathway, ribose-5-phosphate (R5P) is generated. R5P is a 
precursor for nucleotide synthesis and the formation of the reducing equivalent NADPH, 
which is needed for cell proliferation, scavenging of ROS and lipid synthesis (Lu et al. 2013; 
Icard & Lincet 2012; Santos & Schulze 2012). Lipids are used for the construction of cell 
membranes and for energy storage, while nucleotides serve as substrates for continuous DNA 
replication. 
The PPP has two branches, an oxidative and a non-oxidative arm and occurs exclusively in the 
cytoplasm (Figure 1.7). In the oxidative phase, G6P is converted to 6-phosphoglucono-δ-
lactone by glucose- 6-phosphate dehydrogenase (G6PD). 6-phosphoglucono-δ-lactone is then 
hydrolysed to give rise to 6-phosphogluconate, which is then oxidatively decarboxylated by 
6-phosphogluconate dehydrogenase (6PGD) to yield ribulose 5-phosphate (R5P). During the 
oxidative phase, NADP+ participates as the electron acceptor in the two oxidative reactions, 
which are the first and the last reactions. Hence, one molecule of glucose oxidized and 
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metabolized by the PPP can yield net output of two molecules of NADPH. NADPH plays a 
pivotal role in both reductive nucleotide biosynthesis and protecting cells from ROS, which 
are often the main cause of damage to macromolecules and ultimately leading to cell death 
(Jiang et al. 2014). The production of R5P, is generated from six-carbon glucose during the 
non-oxidative phase of the PPP. R5P can be reversibly converted into the glycolytic 
intermediates glyceraldehyde 3-phosphate (G3P) and F6P by TKT and transaldolase. Glycolysis 
and gluconeogenesis coordinate with the PPP to control the cellular production of NADPH 
















Figure 1.7. Schematic representation of the Pentose Phosphate Pathway and glycolysis is 
shown. The oxidative branch of the PPP yields NADPH that can be used in biosynthetic 
reactions for nucleotides, lipids and antioxidant defence. The reversible non-oxidative branch 
produces ribose-5-phosphate from the oxidative branch as well as glycolytic intermediates. 
Solid black arrows represent glycolytic flux, green arrows represent the oxidative branch of 
the PPP, and light blue arrows represent the multi-step processes of the non-oxidative branch 
of the PPP. For clarity, each component of the metabolic process has been abbreviated. PPP, 
pentose phosphate pathway; G6PD, glucose- 6-phosphate dehydrogenase; 6PGD, 6-
phosphogluconate dehydrogenase; TKT, transketolase; Taldo1 (TAL), transaldolase; HK, 
hexokinase; GLUT, glucose transporters; PFK1, phosphofructokinse-1; PGM, 
Phosphoglycerate mutase; PKM2, pyruvate kinase (PK)-M2; LDHA, lactate dehydrogenase A; 
FBP, fructose-1,6-bisphosphate; PEP, phosphoenolpyruvate. From (Jiang et al. 2014) 
 
In cancer, the PPP has received considerable attention in research efforts of recent years. 
Ongoing studies suggest that the PPP is tightly and meticulously regulated in cells and that its 
abnormal regulation leads to uncontrolled biosynthesis (Jiang et al. 2014). As the first and 
rate-limiting enzyme and control site in the oxidative branch of the PPP, G6PD has recently 
received much interest. The activity of G6PD is mediated by various signals, and it acts as a 
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sensor of cellular NADP+ levels. Increased NADP+ activates G6PD by competing with NADPH 
for binding to this enzyme. Therefore, changes in the cellular NADP+/NADPH ratio by 
oxidative stress or other metabolic reprogramming can be expected to impact the PPP flux 
through G6PD (Jiang et al. 2014). G6PD plays an important role in supporting cancer growth 
by supplying NADPH for maintenance of the intracellular redox status of cancer cells. Studies 
have also shown that aberrant transcription factor activity influence G6PD expression and 
activity. Tumour suppressors such as p53 have been shown to inhibit both expression and 
activity of G6PD, and as p53 is one of the most frequently mutated tumour suppressors, in 
many cancers, G6PD function is consequently enhanced (Jiang 2011). Interestingly, G6PD has 
also been shown to be up-regulated by hypoxia in some cancer cells (Gao et al. 2004). 
The non-oxidative pentose phosphate pathway, which allows six-carbon glucose conversion 
to five-carbon ribose for DNA or RNA synthesis, is of utmost importance for the proliferation 
process and accounts for more than 85% of the ribose recovered in tumour nucleic acids (Liu 
et al. 2010). The two enzymes, transketolase (TKT) and transaldolase are the main regulatory 
points in this branch of the PPP. Three human transketolase genes have been identified, 
namely: TKT, transketolase-like 1 gene (TKTL1) and TKTL2 (Langbein et al. 2006; Földi et al. 
2007). TKTL1, a mutated transketolase and not TKT and TKTL2 was shown to be overexpressed 
in a number of cancers. Some examples are; in urothelial, colorectal and non-small cell lung 
cancers where TKTL1 overexpression has been associated with poor patient outcomes 
(Langbein et al. 2006). The Transaldolase (TAL) enzyme on the other hand, has been shown 
to be overexpressed in colorectal cancer (Ma et al. 2009) and was also found to associate with 
metastatic hepatocellular carcinoma (Wang et al. 2011). The overexpression of both TKTL1 
and TAL yields high levels of R5P in cancer cells and interestingly, R5P has been identified in 
metabolic profiling of cancer cells as one of the most strongly up-regulated metabolites in 
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hypoxia (Frezza et al. 2011; Masson & Ratcliffe 2014). The correlation between 
overexpression of these PPP enzymes and their association with tumour aggressiveness 
points to their role in supporting carcinogenesis. 
 
1.5 Oncogenes and transcription factors that drive metabolic reprogramming  
The different hallmark capabilities of cancer cells are all hypothesized to depend upon 
uncontrolled transcription, and deregulated cellular energetics is no exception (Darnell 2002).  
The altered metabolic processes of these cells are a result of oncogene driven mechanisms 
and dysregulation of transcription factors that may direct and promote cell proliferation. 
Oncogenes have also been shown to promote glycolysis in the tumour microenvironment 
(Zeng et al. 2014). The majority of glycolytic enzymes contain evolutionarily conserved, 
consensus Myc-binding sites within their regulatory DNA sequences. The Myc oncogene is 
known to transactivate the expression of LDH-A, which converts pyruvate to lactate thereby 
promoting glycolysis under aerobic conditions (Shim et al. 1997; Feron 2009). On the other 
hand the serine/threonine kinase AKT which falls into the category of oncogenes that 
promote cancer cell survival has been shown to exert direct effects on cancer cell metabolism 
rendering cells to be reliant on aerobic glycolysis for survival, independent of HIF activities 
(Elstrom et al. 2004).  
The tumour suppressor, p53 has previously been shown to negatively regulate the expression 
of Phosphoglycerate Mutase, one of the enzymes required for glycolysis (Kondoh et al. 2005). 
p53 was shown to also influence glycolytic flux by repressing the expression of glucose 
transporters; GLUT1 and GLUT4, limiting the entry of glucose into cells (Puzio-Kuter 2011). As 
discussed previously, p53 inactivates the enzyme G6PD and thereby inhibits the pentose 
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phosphate pathway, adversely affecting the cells’ ability to cope with oxidative stress. In 
cancer however, the p53 function is often inhibited and or the protein itself mutated (Muller 
et al. 2011) allowing cancer cells to escape this negative regulation. 
The above represent only a few examples of oncogenes and transcription factors known to 
play a role in promoting and/or preventing carcinogenesis via metabolic reprogramming.  
Recently the E2F transcription factors have been associated with changes in metabolic 
regulation (Clem & Chesney 2012; Blanchet et al. 2013). The E2F family of transcription factors 
has been known to play a key role in the control of the cell cycle as well as DNA replication in 
association with the retinoblastoma (RB) tumour suppressor (Giacinti & Giordano 2006; 
Macaluso et al. 2005).   
 
1.5.1 The role of hypoxia and HIF in the regulation of cancer cell metabolism 
An underlying theme that emerges from investigations and discussions on reprogrammed 
cancer cell metabolism is the role played by tumour hypoxia. The unique biological 
architecture of solid tumours and the tumour microenvironment indicates the diverse range 
of metabolic properties of different cells within the tumour landscape. The disparity in the 
oxygen distribution across the tumour mass, due to insufficient and impaired tumour 
vasculature often gives rise to hypoxic regions within the tumour. Cancer cells in these regions 
have been known to present a clinical challenge because they are often more resistant to 
radiotherapy and many chemotherapeutic drugs than cancer cells in normoxic regions 
(Wilson & Hay 2011; Horsman et al. 2012; Tong et al. 2013; Zhao et al. 2013). Hypoxic cancer 
cells are therefore thought to increase the probability of tumour recurrence and this is 
possibly a result of their altered metabolic prolife (Flamant et al. 2012). Hypoxia-induced 
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metabolic changes can be largely attributed to the function of the transcription factor called 
Hypoxia-Inducible factor, HIF. HIF plays a major role in multiple aspects of cellular metabolism 
(Figure 1.8). 
HIF is a key regulator in the intracellular response to tumour hypoxia, and to date, this 
transcription factor been shown to regulate more than a hundred downstream targets that 
have been shown to participate tumour metastasis, angiogenesis, energy metabolism, cell 
differentiation and apoptosis (Liu et al. 2012; Liao et al. 2009).  
 
Figure 1.8. Schematic illustrating the action of HIF on multiple aspects of cellular 
metabolism.  HIF plays a major role in glucose metabolism, facilitating glucose uptake in 
cancer cells while also enhancing the activity of glycolytic enzymes and thereby promoting 
lactate production. On the other hand HIF also influences glycogen biosynthesis by regulating 
the major enzymes involved glycogen metabolism. HIF promotes nucleotide synthesis and 
redox regulation through the functions of the PPP by positively regulating the expression of 
G6PD in hypoxia.  The uncoupling of glycolysis to mitochondrial respiration is due to the 
actions of PDK1, a HIF target gene, represented by the red-dashed arrow. (Icard & Lincet 
2012). HIF function is generally associated with macromolecular biosynthesis (like lipid 
biosynthesis) to support proliferation under hypoxic conditions. The blue arrows represent 
flux of the metabolic processes stimulated by HIF function i.e. glucose metabolism and flux 
(glycolysis, glycogen synthesis, the PPP for redox balance in the cells), glutaminolysis which 
supports macromolecular synthesis (Fatty acid synthesis for the biosynthesis of lipids).  From 
(Masson & Ratcliffe 2014) 
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1.6 Identifying targets in cancer metabolism   
Analysis of gene expression patterns together with the biological characterization of 
differentially expressed genes that drive carcinogenesis may provide a means to identify 
druggable targets, where the ‘druggability’ of a molecular target e.g. protein refers to its 
potential to be modulated by small and deliverable, drug-like molecules. In the same way as 
antibiotics target the biosynthetic processes that are unique to microorganisms, the 
possibility of selectively targeting the biosynthetic and energy generating processes of cancer 
cells holds promise as a strategy for improving cancer therapy (Vander Heiden 2011). The 
therapeutic potential of targeting metabolic adaptation in tumours, stems from the 
understanding that altered metabolism is a key consequence of important genetic drivers of 
cancer.  However, the molecular mechanisms by which targeting metabolism could impair 
chemo-resistance are not fully understood and warrant further investigation (Zhao et al. 
2013). 
Earlier in section 1.2, the usefulness of targeting cancer molecular capabilities (hallmarks) to 
halt or abolish uncontrolled proliferation was discussed. Traditional approaches involving the 
treatment of cancer cells based on a singular druggable entity has seen limited success. 
Understanding the molecular changes cancer undergoes has led to approaches using drugs 
that target different cellular pathways. Targeting multiple pathways is discussed by (Tang et 
al. 2013) who states that, “a recent trend in drug development is to identify drug 
combinations or multi-target agents that effectively modify multiple nodes of disease-
associated networks”. Hanahan (2014), on ‘rethinking the war on cancer’ makes a compelling 
case for a combined onslaught on multiple hallmarks and also argues that strategically co-
targeting interdependent hallmarks could for example look like co-inhibiting tumour 
angiogenesis, together with preventing  invasion and metastasis or coupled to disruption of 
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cancer energetics and metabolism. Another option could be to target proliferative signalling 
along with the reactivation of disabled mechanisms for programmed cell death and growth 
suppression, as well as disruption of cancer-cell metabolism (Hanahan 2014). Hanahan 
(2014), also notes that interim steps more realistically will involve even fewer (pairwise) 
combinatorial attacks to test the value and feasibility of such treatment methods. 
Combining current chemotherapeutic agents with targeted disruption of deregulated cellular 
metabolism represents a promising strategy to overcome drug resistance and improve the 
efficacy of current chemotherapeutic agents in cancer patients (Zhao et al. 2013). This will 
require a thorough understanding of cancer cell metabolism in order to select the most 
preferential combinations with minimum toxicity.  
 
1.6.1 Phosphoglucomutase 1 (PGM 1) in cancer 
A microarray study performed in our laboratory using RNA isolated from a cohort of non-
cancerous and advanced-stage cervical cancer patients revealed a group of genes involved in 
glucose metabolism as differentially expressed (van der Watt, PhD thesis, 2009), within the 
group of metabolic enzymes shown to have altered expression in cancer patient tissue, 
Phosphoglucomutase 1 (PGM1) was identified. PGM1 is an evolutionarily conserved enzyme 
that regulates one of the key metabolic carbohydrate trafficking points in prokaryotic and 
eukaryotic organisms (Gururaj et al. 2004). PGM1 belongs to a family of phosphohexose 
mutases. Several phosphoglucomutase isoforms have been identified where PGM1 accounts 
for more than 90% of total PGM activity (Ravazzolo et al. 1985). While PGM2 is known to 
function mainly as a phosphopentose mutase,  PGM3 was found to play a role in the 
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regulation of sulforphane (SFN)-induced apoptosis in prostate cancer cells and showed 
potential as a molecular target for prostate cancer therapy (Lee et al. 2010). 
 As a phosphotransferase, PGM1 catalyses the reversible isomerization of glucose-1-
phosphate to glucose-6-phosphate (with magnesium as a co-factor). G6P becomes a 
precursor for glycolysis and the pentose phosphate pathway, thereby placing PGM1 at 
crossroads of metabolic processes that have been shown to have increased utility in cancer; 
glycolysis, glycogen metabolism and the pentose phosphate pathway.  
 
 
Figure 1.9. PGM1 in relation to the pathways involved in glucose metabolism.  PGM1 sits at 
the crossroads of three metabolic pathways, namely: glycolysis, the pentose phosphate 
pathway and glycogen metabolism. The arrows represent direction of glucose conversion to 
different substrates in the different pathways. In glycolysis, glucose is converted to pyruvate 
then to lactate, in glycogen metabolism G6P is converted to G1P, a precursor in glycogen 
synthesis and in the pentose phosphate pathway G6P is converted to R5P, a precursor for 
nucleotide synthesis and NADPH, the intracellular antioxidant.  
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The p21 protein (Cdc42/RAC)-activated kinase-1 (PAK-1) has been shown to phosphorylate 
and regulate the enzymatic activation of PGM1 in breast cancer cells (Gururaj et al. 2004) and 
recently (Bae et al. 2014) showed that the C-terminal threonine residues of PGM1 are critical 
for its stability and activity.   Research in recent years has shown that PGM1 expression is 
significantly increased in response to hypoxia (Pelletier et al. 2012), however the mechanisms 
that lead to this response are not clear.  
The deficiency of PGM1  was shown to present in a rare disease classified under glycogen 
storage disorders and designated as glycogenosis type XIV (Stojkovic et al. 2009; Lee et al. 
2014; Ondruskova et al. 2014). Recent evidence has shown PGM1 deficiency as a mixed-type 
congenital disorder of protein N- glycosylation which is characterized by the presence of a 
bifid uvula at birth and may serve an early clinical clue to the presence of the syndrome 
(Tegtmeyer et al. 2015).  No studies to date have described the effects of PGM1 
overexpression although association of PGM1 with cancer has surfaced in recent work. Little 
is known about its expression and functional relevance in cancer. This study seeks to 
investigate PGM1 expression, regulation and role in cancer biology. 
 
1.7 Project aims  
This study aimed to determine the role of PGM1 in cancer. The objectives were: 
1. To investigate PGM1 expression of in cancer, transformed and non-cancer cells  
2. To investigate transcriptional regulatory mechanisms associated with PGM1 
expression in cancer cells. 
3. To determine the functional significance of PGM1 in cancer by inhibiting its 




PGM1 EXPRESSION IN CANCER AND TRANSFORMED CELLS 
2.1 INTRODUCTION 
Carcinogenesis results from a multi-step process that is often driven by inherent and acquired 
changes to the expression profile of genes in signalling pathways (Emmert-Streib & Glazko 
2011). The analysis of gene expression patterns in cancer research is routinely and extensively 
used in the mining for novel therapeutic targets and diagnostic markers. This approach 
employs various and diverse techniques ranging from characterising single genes to high-
throughput methods that constitute multiple gene  analysis of transcriptional and proteomic 
changes that take place across different cohorts of cells, tissue types and disease states. Data 
from these techniques is used to provide insight into mechanisms and pathways that 
underpin cancer development and sustain progression. The main objective therefore in 
investigating gene expression patterns is to identify and exploit an underlying finger-print in 
cancer cohorts that is unique to cancer cells and distinctly different from the normal 
phenotype, to aid in the discovery of novel selective treatment strategies for cancer.  
Previously, gene profiling studies to investigate changes that associate with cervical cancer 
development in a cohort of advanced-stage cervical cancer patient specimens compared to 
normal cervical epithelial biopsies was conducted. The data revealed different functional 
groups of genes to have altered expression in cancer including; nuclear transport, cell cycle, 
proteasomal degradation, MAPK signalling pathways, cell adhesion and cytoskeletal 
organization, as well as metabolism (van der Watt 2009; Ward et al. 2011). Amongst these 
functional groups that were investigated, several genes involved in cellular metabolism were 
found to have elevated expression in the cancer patients (van der Watt, PhD thesis, 2009). 
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Pyruvate kinase M2 (PKM2) which catalyses the dephosphorylation of Phosphoenol pyruvate 
(PEP) to produce pyruvate and ATP showed increased mRNA expression in the microarray 
data. PKM2 is specifically overexpressed in cancer cells and its characterization has led to 
investigating the potential of small molecule inhibitors and activators, targeted at this enzyme 
as  cancer therapeutics (Wong et al. 2013). Other glycolytic genes such as Phosphoglucose 
isomerase (PGI), Enolase 1 (ENO 1), Phosphoglycerate kinase 1 (PGK1) and Lactate 
dehydrogenase A (LDHA) were also identified with elevated expression and have previously 
been shown to have increased expression in cancer cells and tissues (Tsutsumi et al. 2009; 
Capello et al. 2011; Chen et al. 2003; Ahmad et al. 2013; Billiard et al. 2013). Studies have 
gone further to investigate the potential of these enzymes in the selective targeting of cancer 
cells as well as assisting in the development of novel prognostic and diagnostic tools against 
cancer (Wong et al. 2013; Song et al. 2014; Chen et al. 2003; Miao et al. 2013).  
 
Genes involved in glucose metabolism although not directly participating in glycolysis that 
showed altered expression by microarray analysis include Glycogen Phosphorylase, muscle 
isoform (PYGL) and Phosphoglucomutase 1 (PGM1). PYGL has been shown to have increased 
expression in cancer and is the main enzyme required for glycogen breakdown or mobilization 
in cells (Favaro et al. 2012). While there are multiple studies that have focussed on the 
association of some of the above mentioned metabolic enzymes with cancer, very little is 
known regarding PGM1 in cancer.  
PGM1 catalyses the preliminary step in glycogen synthesis producing glucose-1-phosphate 
(G1p) from glucose-6-phophate (G6P) which may be processed further for the synthesis of 
the large glycogen polymer. PGM1 also catalyses the last step in the glycogen breakdown 
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process which involves the conversion of G1P into G6P, an intermediate that can be 
channelled to the glycolytic as well as the pentose phosphate pathways.   
In this study we aimed to investigate PGM1 expression levels in cervical cancer patient 



















2.2.1 Expression of metabolic enzymes PGK1, ENO1 and PGM1 in cancer patient tissue.  
With most high throughput methods, single target analysis is required to confirm and validate 
the accuracy of the general, high-throughput screening (Rajeevan et al. 2001; Allison et al. 
2006; Morey et al. 2006). To validate a subset of genes involved in glucose management that 
showed upregulation by microarray analysis (van der Watt et al, PhD thesis, 2009) 
quantitative real time PCR was used. qRTPCR results confirmed a significant increase in the 
expression of the glycolytic genes ENO 1, PGK1 (Figure 2.1 A and B) as well as upregulation of 
PGM1 expression (Figure 2.1 C). As much research has been done on ENO1 and PGK1 in cancer 
and very little is known on PGM1, our study focussed on PGM1 as a potential novel metabolic 





Figure 2.2. PGK1, Enolase 1 and PGM1 mRNA are differentially expressed in cervical cancer. 
qRT-PCR data showing A. PGK1, B. Enolase 1 and C. PGM1 to be significantly increased in 
cervical cancer tissue compared to non-cancerous patient tissue. Data, normalized to β-
Glucuronidase (Gus B) and Cyclophilin D as housekeeping genes, analysed using the 2-ΔΔCt 
Method, non-cancers, n=8, cancer, n=13. * p<0.05.  
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2.2.2 PGM1 protein expression in cancer cell lines of different tissue origin  
Having established that PGM1 mRNA expression was elevated in cervical cancer patient 
material, we next investigated its protein expression by western blot analysis using a panel of 
cervical cancer cell lines (HPV positive, CaSki, HeLa, Me180, SiHa, MS751 and HPV negative 
C33A cells) and a normal primary epithelial cervical cell line (HCX). Our results show higher 
levels of PGM1 protein in the majority of cervical cancer cells compared to HCX cells (Figure 
2.2A and B).  
To investigate whether high PGM1 expression was unique to cervical cancer or a feature of 
cancer of different origins, we used western blot analysis and immunofluorescence to 
evaluate PGM1 expression in cancer cell lines of different tissue origins including; breast and 
oesophageal cancer cell lines. PGM1 protein levels were found to be higher in four of the six 
oesophageal squamous cell carcinomas cell lines compared to the immortalized normal 
oesophageal epithelial cell line (EPC2) (Figure 2.3 A and B). Similarly, higher PGM1 expression 
was observed in (MCF7 and MDA-MB-231 breast cancer cells) compared to the non-
















Figure 2.2. Increased PGM1 protein expression in cervical cancer cell lines. A. Western blot 
for PGM1 protein expression in normal cervical epithelial cells (HCX) and a panel of six cervical 
cancer cell lines, CaSki, HeLa, ME180, SIHA, MS751 and C33A. β-tubulin was used as a loading 
control. B. The histogram is a quantitative representation of PGM1 protein expression relative 
to β-tubulin using Image J Software. Results shown are representative of experiments done 














Figure 2.3. PGM1 protein expression in oesophageal and breast cancer cell lines. A. Western 
blot analysis showing PGM1 protein levels in oesophageal cancer cell lines in relation to the 
normal immortalized oesophageal cells, EPC2. B. Quantification of band intensity relative to 
β-tubulin, showing PGM1 protein expression in oesophageal cancer cells. C. PGM1 expression 
in breast cancer cell lines (MCF7, T47D and MDA-123) compared to the non-tumourigenic 
breast epithelial cells, MCF12A. D. Quantification of band intensity relative to β-tubulin, 
showing PGM1 protein expression in breast cancer cells. Results shown are representative of 
experiments performed in duplicate. 
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2.2.3 PGM1 protein expression in normal versus transformed cells 
We also investigated whether PGM1 expression associated with cellular transformation. This 
was explored by comparing PGM1 expression in normal and transformed fibroblasts. Our 
results show higher expression in the SVW138 transformed cells compared to its normal 
counterpart, WI38 (Figure 2.4 A). Higher expression was observed in the CaSki and the HepG2 
cancer cell lines (Figure 2.4 A and B). HepG2 cells were included for their liver origin and 
thereby consequently high metabolic activity. 
A lower band was observed in W138 cells compared to the transformed and cancer cells lines. 
To investigate whether or not the lower band observed in WI38 cells on Western blot was 
PGM1 or non-specific, these cells were treated with PGM1 targeted siRNA. The top band was 
lost suggesting that the bottom band was a non-specific interaction with the antibody (data 
not shown).  
In addition to western blot analysis, we performed immunofluorescent analysis for PGM1 
expression in normal W138, transformed SVWI38 and cancer cell lines, CaSki and HepG2. 
These results confirm higher PGM1 expression in the cancer cell lines (Figure 2.5A). Together 
the results presented here showed high PGM1 expression in cervical cancer patient material 












Figure 2.4. PGM1 Protein expression in normal, transformed fibroblasts and cancer cells.     
A. Western blot analysis showed higher PGM1 protein expression in the transformed lung 
fibroblasts (SVWI38) and cervical (CaSki) and liver (HepG2) cancer cell lines compared to the 
normal lung fibroblast cells (WI38), β-tubulin was used as a loading control. B. Quantification 
of PGM1 levels relative to β-tubulin done by densitometric analysis. Results shown are 











Figure 2.5. PGM1 Protein expression in normal, transformed fibroblasts and cancer cells by 
Immunofluorescence. PGM1 expression levels are shown to be higher in the CaSki and HepG2 







The increased expression of genes involved in glucose metabolism, in particular glycolysis, is 
a characteristic that has been described previously and in the last decade more data has been 
generated supporting the ‘Warburg effect’. Warburg described that cancer cells showed an 
increased dependence on glycolysis as their major energy source to meet energy demands, 
as opposed to relying on the more energy efficient Krebs and Oxidative Phosphorylation 
processes irrespective of oxygen availability (Warburg 1956; Upadhyay et al. 2013).  
Over the years the Warburg effect has generated much debate on its significance as a 
characteristic displayed by cancer cells, with different reasons put forward as to why it is that 
some cancer cells rely on aerobic glycolysis for their energy needs and survival. Current 
consensus is that both glucose uptake and glycolysis are heightened processes in cancer and 
this has led to the acceptance of these changes in cellular energetics as a cancer hallmark 
(Hanahan & Weinberg 2011). There is growing evidence that genes involved in glucose 
metabolism are differentially expressed in cancer compared to normal. Data generated in our 
laboratory supports the Warburg hypothesis in that, glycolytic genes showed elevated 
expression in the cohort of advance-stage cervical cancers (van der Watt, PhD thesis, 2009). 
Of the genes validated in this study, Enolase 1 which encodes α-enolase (ENO A), an isoform 
found in most adult tissues was confirmed as differentially expressed by qRT-PCR. ENO A 
catalyses the dehydration of 2-phospho-d-glycerate to phosphoenolpyruvate in the second 
half of the glycolytic pathway and has been previously shown to be overexpressed in cervical 
cancer (Capello et al. 2011; Altenberg & Greulich 2004; Bae et al. 2006). ENO A is expressed 
on the cell surface (Moscato et al. 2000) and by acting as a plasminogen receptor it has been 
shown to promote cell migration and cancer metastasis. Phosphoglycerate Kinase 1 (PGK1), 
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also validated in this study, is an ATP-generating enzyme of the glycolytic pathway catalysing 
the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate. PGK1 has been shown to 
be overexpressed in colon cancer and this increased expression has been linked to metastasis 
(Ahmad et al. 2013). Our data showing PGM1 expression to be increased in cervical cancer 
compared to non-cancerous cervical tissue is a first to our knowledge. PGM1 functions to 
reversibly convert G1P to G6P and can therefore influence the pentose phosphate pathway, 
glycolysis and glycogen synthesis.  
Studies such as those done by (Favaro et al. 2012) and  (Pelletier et al. 2012) show elevated 
PGM1 expression in response to specific biological stimulants such as treatment with 
Bevacizumab, an anti-angiogenic drug and  hypoxic stress. Our data shows that even outside 
of external stimuli PGM1 expression levels were higher in cancer cells and transformed cells 
compared to normal. High PGM1 expression appears not to be unique to cervical cancer cells 
as other cancer cell lines that we investigated such as breast and oesophageal cancers also 
show high PGM1 levels. We observed the high PGM1 protein levels in the liver cancer cell 
line, HepG2. The high expression in HepG2 cells is likely a result of the inherent function of 
liver tissue as the body’s metabolic centre and in particular its role in maintaining blood-sugar 
homeostasis through monitoring glucose metabolism and regulation. A transformed cell line 
SVWI38 showed higher PGM1 expression levels compared to the normal WI38 cell line 
suggesting that PGM1 up-regulation associates with the transformed phenotype and could 
possibly be an early event in cancer development.  
Elevated PGM1 expression in the cervical cancer cell lines was more pronounced in the HPV 
positive cell lines as opposed to the HPV negative, C33A cell line, implying a possible 
involvement of the activity of HPV oncoproteins in altered PGM1 expression in cervical 
41 
 
cancer. HPV oncoproteins have been directly and indirectly implicated in changes in 
metabolism and the expression of metabolic enzymes (Mclaughlin-drubin & Münger 2010). 
For example, the HPV 16 E7 protein has been shown to associate with and alter the activity 
of the pyruvate kinase (PK) one of the glycolytic enzymes. HPV 16 E7 transformed cells have 
been shown to exhibit high Pyruvate Kinase (PK) expression which leads to an increased 
glycolytic activity (Zwerschke & Mazurek 1999). This oncoprotein has been shown to 
allosterically activate α-glucosidase, an enzyme involved in glycogen catabolism (Zwerschke 
et al. 2000; Chakrabarti & Krishna 2003). PGM1 expression was also increased in cancer cell 
lines that are not necessarily associated with HPV infection. The HPV oncoprotein E7 is 
reported to be responsible for the loss of the retinoblastoma (Rb) tumour suppressor function 
in HPV-induced cancers. HPV E7 leads to the rapid ubiquitination and consequent degradation 
of Rb in HPV infected cells. This results in a release of a block on genes regulated by RB. Non-
HPV associated cancers cells, Rb ‘loss of function’ can occur as a result of deactivating 
mutations or deletions of the gene that encodes this protein (Liu et al. 2004; Giacinti & 
Giordano 2006). Loss of Rb would associates with the uncontrolled expression of genes that 
were normally held at bay by its inhibitory functions. The transcriptional regulation of PGM1 






TRANSCRIPTIONAL REGULATION OF PGM1 EXPRESSION IN TRANSFORMED 




The classic enzymology of PGM1 has been extensively reported while the regulation of its 
expression in cancer has seen limited investigation (Bae et al. 2014). Phosphorylation of serine 
108 of PGM1 has been shown to act as a phosphoryl group donor to producing G-1,6-BP 
(Pouysségur et al. 1977), and p21-activated kinase 1 (Pak1) was shown to phosphorylate 
threonine 466 of PGM1 and enhance its enzymatic activity (Gururaj et al. 2004). PAK 1 has 
been shown to be upregulated in a number of cancers including breast, lymph, bladder and 
ovarian cancer (Balasenthil et al. 2004). PAK 1 was also shown to be expressed in cervical 
cancer and its functions include promoting cell proliferation and inhibiting apoptosis (Tsin-
Wah 2013).  To date there have been no published reports on the transcriptional regulation 
of PGM1 expression in cancer cells. 
A bioinformatics search for putative transcription factor (TF) binding sites in the region 2kb 
upstream and 101 bp downstream of PGM1’s transcription start site (TSS) was performed. A 
number of TFs that potentially bind to this regulatory region of the PGM1 promoter were 
identified. Of these factors that could potentially bind to the PGM1 gene, E2F and HIF proteins 
were of particular interest, as these TFs commonly associate with cancer development (Lum 
et al. 2007; DeBerardinis et al. 2008; Dang et al. 2008; Porporato et al. 2011; Masson & 
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Ratcliffe 2014; Nevins 2001; van der Watt et al. 2011; Ward et al. 2011; DeGregori & Johnson 
2006). 
A number of studies have demonstrated that E2F proteins are involved in the control of the 
expression of genes important for DNA replication as well as promoting cell cycle progression 
and consequently proliferation (Nevins 1998; Dyson 1998; Ishida et al. 2001). The 
retinoblastoma protein (pRB) and other pocket binding proteins on the other hand suppress 
E2F-mediated transcription in cells during progression through the early G1 phase, ascribing 
tumour suppressive functions to these proteins (Choi et al. 2014). pRB and E2F are often 
described as opposing molecules that control the G1/S-phase transition. The mechanisms 
involved in their interactions however, are far more complex, involving different family 
members that form complexes which can either activate or repress promoter activities (Dyson 
1998). Few studies have demonstrated a direct association of E2F proteins to metabolic 
function, despite an intuitive extrapolation that high proliferative rates of cancer cells may 
require a proportionate quantity of cellular components (Blanchet et al. 2013; Clem & 
Chesney 2012). For example, the pre-cursors of DNA replication and substrates of nucleotide 
synthesis produced by pathways such as the pentose phosphate pathway, a pathway that can 
be influenced by PGM1.  
The transcription factor, hypoxia-inducible factor-1 (HIF-1) is  the main regulator responsible 
for inducing the expression of genes that facilitate adaptation and survival of cells from 
normoxia (approximately 21% oxygen) to hypoxia (approximately 1% oxygen) (Wang et al. 
1995; Ke & Costa 2006). Diminishing oxygen gradient in tumours often occurs as a result of 
impaired or inadequate vasculature which consequently induces HIF. HIF functions as a 
heterodimer consisting of HIF-1α and HIF-1β (also called the aryl hydrocarbon receptor 
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nuclear translocator [ARNT]) in most cells (Keith et al. 2001; Hu et al. 2003). The oxygen 
regulated α subunit has three isoforms: HIF-1α, HIF-2α, and HIF-3α while the constitutively 
expressed β subunit has only two isoforms HIF-1β and HIF-2β (Wang et al. 1995; Semenza 
2009). The α-subunit is transported into the nucleus and dimerizes with the β subunit when 
oxygen concentrations are below 6% (Jiang et al. 1996). Under normoxic conditions, HIF-1α is 
synthesized and hydroxylated by prolyl hydroxylase domain (PHD) proteins to facilitate 
binding to the von Hippel-Lindau protein (pVHL), which targets HIF-1α for ubiquitination and 
ultimately marks the protein for degradation by the 26S Proteasome. In hypoxia this cascade 
is inhibited allowing the HIF heterodimers to bind to their target genes (Salceda & Caro 1997). 
HIF has been shown to promote a glycolytic phenotype in cancer, with recent evidence 
showing an association with glycogen accumulation and enhanced expression of genes 
involved in glycogen metabolism.  
The objective in this study was, to investigate transcriptional regulatory mechanisms that may 
account for the high levels of PGM1 expression in cancer cells, with particular focus on the 
roles of E2F an HIF1. The cell culture models used in the following experiments were mostly 
the HPV positive HeLa and CaSki cells (which in some instances, HeLa cells were selected over 
the CaSki due to difficulties with  transfection efficiencies) and C33A, HPV negative cervical 








3.2.1  Cloning of the PGM1 promoter and bioinformatics search for transcription factor 
binding sites  
To determine transcriptional regulatory mechanisms that associate with elevated PGM1 
expression in cancer cells, a bioinformatics analysis of the region -2Kb upstream of the 
transcription start site and +101 downstream was searched for putative transcription factor 
binding sites. The in silico search was done using the MatInspector software programme 
(https://www.genomatix.de/). Search outputs identified seven potential E2F sites at various 





Figure 3.1. Human PGM1 promoter map. Schematic representation of data from a 
MatInspector search for transcription factor binding sites in the (-2000 to +101) region of the 
PGM1 promoter, using the genomatix (MatInspector) software suite. The map shows the co-
ordinates of putative binding sites for the three transcription factors, E2F and HIF 1, as 
denoted in search output and their corresponding location on the PGM1 promoter. Only the 




Primers for PCR were designed to span the region of approximately 2 Kb upstream of the 
transcription start site (TSS) of the PGM1 gene, together with approximately 100 bp of the 5’ 
untranslated regions (downstream from the TSS). This region was PCR amplified and 
subcloned into pGEM-T-Easy. After screening and confirming correct inserts by sequencing, 
the (-1988 to +101) PGM1 promoter insert was released by double digesting plasmids with 
NheI and HindIII restriction enzymes. The (-1988 to +101) fragment was then cloned into the 
pGL3-Basic vector upstream of a luciferase reporter construct (Figure 3.2A), allowing for 
quantitative analysis of PGM1 promoter activity in cells. The PGM1 promoter fragment cloned 
into pGL3-basic was checked by restriction enzyme digestion (Figure 3.2A ii). The pGL3-
pPGM1 (-1988/+101) promoter construct was transfected into CaSki cells and luciferase 
activity as a measure of promoter activity showed 10-fold higher activity with the (-1988 to 








Figure 3.2. Promoter activity of human PGM1 (-1988 to + 101) cloned into pGL3- Basic 
reporter vector. A. (i) Schematic illustration of the cloned PGM1 promoter (-1988 to +101) in 
pGL3-Basic. The promoter fragment was cloned upstream of the luciferase reporter gene 
using Nhe l and Hind III restriction sites in the vector’s multiple cloning site. (ii)  Restriction 
enzyme digest of the pGl3- Basic vector (lane 1) and the vector containing insert (pGL3-
pPGM1 -1988/+101) (lane 2) with Nhe1 and Hind III to release the promoter fragment. Digests 
were electrophoresed on a 1% agarose gel and visualized accordingly, the release of a 2089 
bp DNA fragment indicated successful cloning of the PGM1 promoter into pGL3-Basic. B. The 
empty vector and pGL3-pPGM1 were transfected into CaSki cells and luciferase activity 
measured. Results show significant promoter activity in the PGM1 (-1988 to +101) construct 
compared to the empty vector (*p < 0.05). The Renilla reporter was used as an internal control 
for transfection efficiency. Results shown are the mean ± SEM of experiments performed in 
triplicate and repeated at least two independent times. 
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3.2.2  PGM1 protein expression in transformed and cancer cells in relation to PGM1 
promoter activity. 
PGM1 protein expression was shown to be increased in the cancer and transformed cells 
when compared to the normal cell lines.  FGo, CCD1068-SK and WI38 normal fibroblast cells 
showed relatively lower endogenous PGM1 protein expression compared to transformed 
(SVWI38, CT1) and cancer cell lines (CaSki and HeLa) (Figure 3.3 A and B). As WI38 and 
CCD1068-SK cells proved difficult to transfect, promoter assays were done in FGo cells as a 
representative normal cell line. The pGL3-pPGM1 (-1988/+101) promoter construct was 
transfected into FGo, SVWI38, CaSki and HeLa cell lines and dual-luciferase assays used to 
compare PGM1 promoter activity. Results showed significantly higher (-1988/+101) PGM1 
promoter activity in the SVWI38  transformed cells and in CaSki and HeLa cancer cell lines 







Figure 3.3. -1988 to +101 PGM1 promoter activity in normal, transformed and cancer cells 
correlates with endogenous protein levels. A. PGM1 Protein expression in by western blot 
analysis shows higher expression in transformed fibroblasts (SVWI38 and CT-1) and cervical 
cancer cells (CaSki and HeLa) compared to the normal fibroblasts (FGO, CCD1068-SK and 
WI38). B. Quantification of PGM1 protein expression relative to β-tubulin. Results are 
representative of experiments performed at least two independent times C. PGM1 promoter 
activity in normal and transformed fibroblasts and cancer cells transfected with the pGL3-
pPGM1 (-1988/+101) for 48 hours, a Dual luciferase assay was used and luciferase activity 
normalized to pTK-renilla.  Results show higher expression in the transformed cell line 
(SVWI38) and cancer cell line CaSki and HeLa and compared to FGo normal fibroblasts. Results 
show are the mean ± SEM of experiments performed in triplicate and repeated at least two 
independent times.  
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3.2.3  The effect of E2F/DP1, E7 Inhibition and RB overexpression on PGM1 expression and 
promoter activity in cervical cancer cells 
E2F family members function as heterodimers of an E2F member with a DP family member. 
DP1 dimerizes with E2F to enhances both DNA binding and transactivation activities (Zaragoza 
et al. 2010). Recent studies have implicated the E2F/RB axis in the control of metabolic 
function, a limited number of which have linked E2F family members with glycolytic control 
(Blanchet et al. 2013; Clem & Chesney 2012). One such study showed that E2F1 acts as a 
switch between the glycolytic mode during proliferation and the oxidative phosphorylation 
under dormant or stressful conditions (Yeo et al. 2011). The genes associated with this E2F 
regulated switch are not known and currently under investigation. 
In order to determine whether E2F influences the expression and activity of PGM1 in cancer, 
we inhibited the expression of its binding partner DP1 using siRNA. DP1 was silenced instead 
of directly targeting individual E2F family members because DP1 is essential for the function 
of all the different E2F proteins, thereby allowing for simultaneously inhibition as opposed to 
requiring different siRNA’s for all nine different E2F proteins. Western blot analysis showed a 
reduction in PGM1 protein levels in CaSki cells treated with a DP1 targeting siRNA which 
inhibits the function of most E2F members (Figure 3.4 A). Since E2F activity in cervical cancer 
cells associates with the HPV E7 onco-protein, we investigated whether inhibiting HPV16 E7 
would have an effect on PGM1 protein expression. HPV E7 is known to cause the 
phosphorylation of the retinoblastoma protein (pRb), which targets Rb protein for 
degradation thereby freeing E2F to bind to its downstream target genes. Our results show 
that E7 inhibition resulted in a reduction in phosphorylated-Rb levels which associates with a 
consequent decrease PGM1 protein expression (Figure 3.4 B). By inference, a decrease in 
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phosphorylated Rb suggests that functional Rb can bind and inhibit E2F and thereby interfere 
with PGM1 expression. Overexpressed Rb in HPV positive and negative cervical cancer cell 
lines, HeLa and C33A also resulted in a reduction in PGM1 promoter activity (Figure 3.4 C (i) 
and (ii)). These results suggest a role for E2F in the regulation of PGM1 protein expression and 
promoter activity. 
 
3.2.4  E2F/DP1 binds regions within the PGM1 promoter  
To determine whether the E2F/DP1 heterodimers could directly bind to the PGM1 promoter 
at the regions containing putative E2F binding sites (with the consensus sequence 5’-
TTTSSCGS-3’; where S denotes either C or G), Chromatin Immunoprecipitation (ChIP) assays 
were performed using chromatin prepared from CaSki cells. ChIP primers spanned the PGM1 
promoter regions from (-784 to -579), (-257 to -77) and (-110 to +77) (Figure 3.5A). Our results 

















Figure 3.4. DP1 and E7 inhibition and RB overexpression in cervical cancer cells decreases 
PGM1 protein expression and promoter activity. A. Western blots showing PGM1 protein 
levels after DP1 inhibition using siRNA in CaSki cells. B. HPV16 E7 siRNA was used to inhibit E7 
expression in CaSki cells and a significant reduction in phosphorylated Rb was observed and 
correlated to reduction PGM1 protein expression C. Rb overexpression in cervical cancer cells 
(i) HeLa and (ii) C33A and (-1988 to +101) PGM1 promoter activity was investigated by a dual 
luciferase assay. Renilla was used as an internal control. Results shown are the mean ± SD of 





Figure 3.5. Binding of E2F/DP1 to the PGM1 promoter in the regions -784 to -579 and -257 
to -77. A Schematic representation of the location of the primers used for the ChIP assay. 
Samples of sonicated chromatin from CaSki cells, immunoprecipitated with a DP1 antibody as 
indicated. DNA Isolated from the immunoprecipitated material was amplified by PCR using 
primers 1, 2 and 3 spanning the regions containing the different putative E2F sites. Amplified 
fragments were analysed by electrophoresis on a 2% agarose gel. Results show direct binding 




3.2.5 Analysis of PGM1 promoter activity through promoter deletion constructs 
Having established binding of the E2F/DP1 complex at different sites within the (-1988 to 
+101) PGM1 promoter fragment, we sought to determine the regions necessary for E2F 
activation of the PGM1 promoter in cancer cells. A series of deletion constructs were thus 
synthesized using forward primers  designed to incorporate a Nhe l restriction sites such that 
promoter deletion constructs spanning (-587 to +101) and (-135 to +101)  could be 
synthesized. All constructs were confirmed by restriction digestion analysis using Nhe I and 
Hind III (data not shown) and transfected into CaSki, HeLa and C33A cells. Results in all cell 
lines indicate that the shortest promoter fragment (-135 to +101) retained promoter activity 
(Figure 3.6). Interestingly deletion of the -1988 to -135 regions resulted in small but significant 
increase in promoter activity suggesting the presence of possible repressor elements in this 
















Figure 3.6. Activity of PGM1 promoter deletion constructs in CaSki HeLa and C33A cells. 
Luciferase reporter constructs containing deleted fragments of the human PGM1 promoter 
were transfected transiently into CaSki, HeLa and C33A cells, respectively. TK-Renilla-Luc was 
used as an internal control for transfection efficiency. Results shown are the mean ± SEM of 





3.2.6  The effect of HPV E7 inhibition on PGM1 promoter activity  
To further investigate the functional significance of (-135 to +101) region of the PGM1 
promoter, HPV16 E7 was inhibited using siRNA in CaSki as a means to release the block on Rb 
and hence result in E2F inhibition. A reduction in (-135 to +101) PGM1 promoter activity was 
observed when E7 was inhibited (Figure 3.7). This data further suggests that E2F family 






Figure 3.7. HPV E7 Inhibition influences PGM1 promoter activity in the short -135/+101 
promoter fragment. Luciferase reporter constructs containing the (-135/+101) region of the 
human PGM1 promoter were transfected transiently into CaSki cells, simultaneously with HPV 
E7 siRNA used to inhibit E7 expression in CaSki cells. Inhibition of E7 in cells transfected with 
the (-135 to +101) PGM1 promoter fragment showed a significant reduction in promoter 
activity (*p < 0.05). Total protein was used as an internal control. Results shown are the mean 
± SEM of experiments performed in triplicate and repeated at least two times. 
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3.2.7  Site directed mutagenesis of putative E2F/DP1 binding sites in the (-135 to +101) 
PGM1 promoter region. 
 
Using siRNA against E2F/DP1 and in vivo ChIP assays we have identified E2F/DP1 as a potential 
regulator of PGM1 expression. Our promoter deletion assays showed that the (-135 to+101) 
region of the PGM1 gene contained elements sufficient for promoter activity. The 
bioinformatics search for putative transcription factors within this region revealed three 
putative E2F/DP1 binding sites at positions (-95 to -88), (+34 to +42) and (+80 to +87). These 
three sites were mutated to investigate their requirement for PGM1 promoter activity. The 
site mutations were done according to published sequence conversion to a NheI restriction 
site (van der Watt et al. 2011) with the exception of the (-95 to -88) (E2Fa) site which was 
converted to a Xho I site due to difficulties with primer design in this region (Figure 3.8A). In 
all instances, mutagenic sites were verified by submitting the sequence to MatInspector 
(https://www.genomatix.de/) to check for the absence of the E2F binding site after mutation. 
Our data showed that mutating each of the three putative E2F/DP1 binding sites had no effect 
on PGM1 promoter activity in comparison to the wild-type promoter construct (Figure 3.8 A 
and B). This suggests that E2F/DP1 regulation of the PGM1 promoter may be at regions not 
recognized as classic E2F binding sites or that E2F regulates PGM1 expression in an indirect 












Figure 3.8. Site-directed mutagenesis of the E2F sites in the -135 to +101 PGM1 promoter 
fragment shows no change in activity. Mutations of the putative E2F binding site were 
synthesised using the PGM1 (-135 to +101) promoter construct at positions (-95 to -88), (+34 
to +42) and (+80 to +87) positions (marked as E2F a, b and c respectively). A. The respective 
consensus sites are in red, with the bases chosen for mutation in green and the mutated bases 
in lower case bold. Restriction sites were introduced and are underlined. Only the sense 
mutagenic primer is indicated (antisense primers are described in Chapter 6). Mutagenesis 
was performed to eliminate the putative E2F. B. Effect of putative E2F binding site mutations 
on PGM1 (-135 to +101) promoter activity in CaSki cells. Wild type and mutated constructs 
were transfected into CaSki cells and luciferase activity determined. No significant changes in 
luciferase activity we observed between wild-type and mutated sequences (*p < 0.05). 




3.2.8  PGM1 expression and promoter activity under conditions of hypoxia 
The transcription factor, HIF 1, when activated has been shown to promote the expression 
and activation of many enzymes involved in glycolytic metabolism (Semenza 2010). We 
identified a putative hypoxia-responsive-element (HRE) at position (-156 to -152) in the 
bioinformatics search for potential TF binding sites within the PGM1 promoter, where the HIF  
heterodimers may bind to the consensus sequence 5’-NCGTG-3’, where N represents an A or 
G.  
Since HIF1 is responsive to hypoxia we sought to investigate whether hypoxia influenced 
PGM1 expression in cancer cells and whether this response was dependent on HIF1 function. 
Nickel (II) sulphate (NiSO4) and cobalt (II) chloride (CoCl2) are known to mimic hypoxia in part 
by inhibiting the function of prolyl hydroxylase domain-containing enzymes (PHDs), thereby 
stabilizing HIF (Nardinocchi et al. 2009; Rohwer & Cramer 2011; Stenger et al. 2011). HIF, upon 
PHD inhibition is then free to bind to the promoters of its target genes and regulate their 
expression. Our results show that both hypoxia mimics CoCl2 and NiSO4 stimulated the 
expression of HIF1α in CaSki and HeLa cells at a concentration of 0.5 mM. The increase in 
HIF1α levels associated with an increase in PGM1 levels (Figure 3.9 A and B). Similar to data 
observed with protein expression, 0.5 mM NiSO4 treatment resulted in a significant increase 
in PGM1 mRNA levels (Figure 3.10 A). 
To determine whether the change in PGM1 mRNA expression in response to hypoxia was due 
to transcriptional events or stabilization of the mRNA, cells were treated with Actinomycin D, 
which acts by interfering with de novo mRNA synthesis, prior to treatment with the hypoxia 
mimicking agent, NiSO4. The induction of PGM1 mRNA was inhibited by actinomycin D 
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treatment (Figure 3.10 B), suggesting that hypoxia affected its transcription rather than its 
stability.  
To further determine whether hypoxia inducing agents regulated PGM1 expression, we 
monitored its effects on (-1988 to +101) PGM1 promoter activity. Both 0.5 mM NiSO4 and 
CoCl2 at 0.5 mM treatment resulted in a significant increase in (-1988/+101) PGM1 promoter 
activity (Figure 3.11 A and B). Together these results show that hypoxia mimicking agents 


























Figure 3.9. Effect of hypoxia mimics A. CoCl2 and B. NiSO4 on PGM1 protein expression 
CaSki and HeLa cells were grown until approximately 80% confluent, then treated with 0, 0.25 
and 0.5mM CoCl2 and 0, 0.5 and 1 mM NiSO4 respectively. Whole cell lysates were harvested 
after 24 hrs post treatment and subjected to western blot analysis to detect HIF1 α and PGM1 
protein expression. β-tubulin was used as a loading control. HIF1 α induction was observed in 
both cell lines with a simultaneous increase in PGM1 expression observed at concentrations 






Figure 3.10. Hypoxia mimicking agents induce PGM1 mRNA expression and Actinomycin D 
inhibits hypoxia-induced PGM1 mRNA expression. A. RNA was extracted from HeLa cells 
treated with 0.5 mM NiSO4 and qRT-PCR performed with data normalized to B-actin, 
experiment was repeated twice in triplicate, * p < 0.05 B. HeLa cells were cultured in 25mM 
glucose containing media, then treated with 1µg/ml Actinomycin D for 30 min, the Act D was 
removed then cells subjected to 0.5 mM Nickel sulphate overnight. The data shown is the 
mean ± SEM of experiments performed in triplicate and repeated at least two times, * p < 
0.05. Hypoxia induced PGM1 mRNA expression and the hypoxia-induced PGM1 expression 





Figure 3.11: Hypoxia mimicking agents, NiSO4 and CoCl2 induce PGM1 promoter activity in 
cervical cancer cells. HeLa cells were cultured in 25 mM glucose and transfected with the -
1988 to +101 PGM1 promoter constructed overnight then treated with 0.5 mM A. NiSO4 and 
B. CoCl2 for 24hrs. All data was normalized to total protein. Results shown are the mean ± 






3.2.9  In vivo binding of HIF1α to the PGM1 promoter  
A bioinformatics search for TF binding sites identified a potential hypoxia-responsive element 
(HRE) at position (-156 to -152) on the PGM1 promoter (Figure 3.12 A). To investigate whether 
HIF1α bound to this region, ChIP assays with chromatin prepared from HeLa cells in normoxia 
and cells treated with 0.5 mM NiSO4 to mimic hypoxia, were performed using primers that 
spanning the region (-257 to -77).  Results show no change between the negative control and 
the HIF1α antibody pulldown in conditions of normoxia (Figure 3.12B). An increase in HIF1α 
pulldown relative to the negative control was observed in hypoxia mimicked conditions 







Figure 3.12. HIF 1 a binds the (-257 to -77) region of the PGM1 promoter. DNA Isolated from 
control and HIF1α immunoprecipitated material was amplified by A. PCR using primers 
spanning the putative HIF 1 site at -257 to -77 region of the PGM1 promoter. Samples of 
sonicated chromatin from HeLa cells either in B. normoxia or subjected to C. treatment with 
0.5 mM NiSO4 to mimic hypoxia, then immunoprecipitated with a HIF1 α antibody as 





3.2.10 Analysis of hypoxia-induced PGM1 promoter activity  
Mutation of the putative HIF1α binding site was carried out in order to determine whether 
this region contained a true Hypoxia Responsive Element (HRE) or HIF1α binding site. This was 
done by site directed mutagenesis in which three bases of the consensus site were converted 
into a BamHI restriction enzyme site (Figure 3.13A). The mutations were checked by both 
restriction enzyme digestion and sequence analysis. Hypoxia-induced promoter activity from 
the mutant construct was compared to that of the wild-type PGM1 (-1988 to +101) construct 
in HeLa and SVWI38. Results show in both cell lines that mutating the putative HIF1α binding 
site did not inhibit hypoxia induced activation (Figure 3.13 B and C). The possibility of an HRE 
in other locations within the -1988 to +101 promoter was thus investigated. 
PGM1 promoter deletion constructs were transfected into HeLa cells, and cells were exposed 
to hypoxia mimicking agents. This was done order to determine the HIF responsive regions 
and ascertain whether the shortest deletion constructs (which excludes the (-156 to -152) 
region, but contains the highly conserved (+19 to +23) region) would respond to hypoxia. Our 
result show that all constructs including the shortest (-135 to +101) PGM1 promoter 
fragment, showed enhanced promoter activity in response to the treatment with hypoxia 
mimicking reagents (Figure 3.14), suggesting that a hypoxia-responsive element could be 
present in the (-135 to +101) region. 
Sequence alignment of the PGM1 promoter region across multiple species and manual search 
revealed another potential HRE which appeared to be highly conserved at (+19 to +23) 







Figure 3.13: Site-directed mutagenesis of the (-156 to -152) putative hypoxia responsive 
element (HRE) in the PGM1 (-1988 to +101) promoter. A. Mutation of the HRE for HIF1 
binding was carried out by site-directed mutagenesis using mutagenic primers, with the 
PGM1 (-1988 to +101) promoter construct as a template. The consensus HRE is in red, with 
bases chosen for mutation in green. Mutations in the HRE are marked by lower-case bold 
type. A BamHI restriction site was introduced and is underlined. The sense mutagenic primer 
is depicted. B. and C. Mutation of the HRE has no effect on the PGM1 (-1988 to +101) 
promoter activity in response to hypoxia (treatment with 0.5 mM NiSO4) in SVWI38 (B) and 
HeLa (C) cell lines. Data was normalized to total protein. Experiments are shown as the mean 






Figure 3.14: Activity of PGM1 promoter deletion constructs in response to hypoxia. 
Luciferase reporter constructs containing deleted fragments of the human PGM1 promoter 
were transfected transiently into HeLa cells then treated with 0.5 mM NiSO4 for 24 hrs to 
mimic hypoxia in cells.  Protein concentration was used to normalize data. All PGM1 promoter 
fragments showed a significant increase activity in response hypoxia as well as the (-135 to 
+101) fragment (*p < 0.05). Results shown are the mean ± SEM of experiments performed in 










Figure 3.15: Sequence alignment showing HRE at -162 and another putative and conserved 
HRE at +19. Schematic representation of data from Multalin, the programme used to align 
wild-type (-2000 to +101) regions of the PGM1 promoter across different species. The position 
of the putative (-156 to -152) HRE was identified using from MatInspector (indicated in the 
blue box) and manually identified (+19 to +23) HRE conserved across species (indicated in the 
green box).  
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The potential HRE site located in the (+19 to +23) region was then mutated by site directed 
mutagenesis and the mutated promoter analysed for transcriptional activation under 
normoxia and hypoxic conditions. Our data shows that the response of the mutant -135 to 
+101 PGM1 promoter fragment behaved in similar fashion to the wild-type promoter (Figure 
3.16) suggesting that the sequences around the (+19 to +23) region are not involved in HIF1α 
regulation of the PGM1 promoter. 

























Figure 3.16: Site-directed mutagenesis of the (+19 to +23) region of the PGM1 promoter. 
Mutation of the (+19 to +23) region by site-directed mutagenesis using mutagenic primers, 
with the PGM1 (-135 to +101) promoter construct as a template. A. The consensus HRE is 
shown in red, with bases chosen for mutation in green. Mutations in the HRE are marked by 
lower-case bold type. A BamHI restriction site was introduced and is shown B. Mutation of 
the HRE does not reduces PGM1 (-135 to +101) promoter activity as measured by luciferase 
assays in response to hypoxia (treatment with 0.5 mM NiSO4) in the HeLa cell line. Total 
protein was used to normalize all data. Results shown are the mean ± SEM of three 





Differential expression patterns in genes encoding enzymes involved in metabolism have 
been observed in a number of cancers, and deregulation of some of these genes has been 
linked to specific clinical outcomes in cancers (Cavalieri et al. 2007; Chaika et al. 2012). 
Alterations in genes involved in glucose metabolism has also been described and associated 
with cell survival in pancreatic cancer (Gapstur et al. 2007). Investigating transcriptional 
regulatory mechanisms that underpin these differential patterns in gene expression to 
account for the altered metabolic profile of cancer cells can assist in providing insight into 
processes and pathways that drive and sustain carcinogenesis. 
  
Here we cloned the PGM1 promoter in order to investigate the transcriptional mechanisms 
responsible for the high expression of PGM1 seen in cervical cancer cells. We show here that 
changes in PGM1 gene expression in cancer compared to normal are likely, associate with the 
transcription factor activities of E2F and HIF as endogenous levels of PGM1 expression 
responded to alteration in the presence of these transcription factors.  
 
Rb has been shown to suppress the transcription of the metabolic enzymes such as; thymidine 
kinase (TK) and dihydrofolate reductase (DHFR), which are both required for the synthesis of 
nucleotides. Rb’s negative effect on metabolic enzymes occurs through physical interaction 
with E2F proteins which result in the suppression of energetic and anabolic functions in 
metabolism (Clem & Chesney 2012). In our study, we show that when E2F function is inhibited 
via DP1 siRNA treatment or overexpression of RB or through HPV16 oncoprotein E7 siRNA 
targeting, endogenous PGM1 levels are inhibited, suggesting that E2F/DP1 regulates PGM1 
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expression. We also show direct binding of DP1 (suggesting E2F/DP1 complexes) to the PGM1 
promoter via ChIP assay.  
 
The region of the PGM1 promoter necessary for E2F/DP1 regulation of PGM1 expression was 
assessed via generation of deletion constructs of the PGM1 promoter. Our results showed 
that although binding of the DP1 protein was observed using ChIP assays in the areas spanning 
the putative E2F sites across the (-1988 to +101) promoter, the region (-135 to +101) was 
sufficient for maintaining high PGM1 promoter activity. We also observed that E7 inhibition 
significantly decreased PGM1 promoter activity in this region. Mutation of the three putative 
E2F sites (a, b and c) in the (-135 to +101) region by site directed mutagenesis however, had 
no effect on the activity of the promoter construct. These findings using artificial promoter 
constructs did not reconcile with what was observed on endogenous PGM1 levels. It is 
possible that there are other factors complexed with DP1 that could bind to the PGM1 
promoter in -135 to +101 region and contribute the high PGM1 expression observed. DP1 has 
been reported to have other binding partners apart from E2F (Harbour & Dean 2000; De La 
Luna et al. 1999). Studies have shown p53 to compete with E2F1 for DP1 binding and 
mutational analysis to define within DP-1 a C-terminal region required for the interaction with 
p53, thereby providing an alternative mechanism through which p53 can regulate cell 
proliferation (Sørensen et al. 1996). A recent study also proposed novel functions of DP1 in 
which transcriptional activities were independent of E2F proteins to co-ordinate the Wnt/β-
catenin signalling (Kim et al. 2012). There is also a chance that the obstruction of only one site 
at a time would not be sufficient to eliminate all promoter activity and therefore future work 
could possibly look at investigating the effects of a “triple mutant” in which all three sites 
within the (-135 to +101) region are removed. 
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Several studies have implicated hypoxia as a promoter of the expression of genes involved in 
glucose metabolism (Lum et al. 2007; DeBerardinis et al. 2008; Brahimi-Horn et al. 2011). 
More recently, PGM1 protein expression was shown to increase in response to hypoxic 
environments, such as seen when cancer cells were treated with anti-angiogenic agents 
(Favaro et al. 2012; Pelletier et al. 2012). To mimic hypoxia we treated cells with hypoxia 
mimicking agents which inhibit the function of PHDs thereby stabilizing HIF and allowing for 
investigations on the effects of HIF activation on PGM1 expression. We showed that PGM1 
protein, mRNA and promoter activity was increased in response to hypoxia thereby validating 
these recent observation in our current context.  
 
An in silico search for potential HIF responsive elements identified a putative HRE at position 
(-156 to -152) in the PGM1 promoter, and ChIP assays showed binding of HIF-1α within the 
region surrounding the putative HRE. Artificially mutating the (-156 to -152) region of the 
PGM1 promoter had no effect on PGM1 promoter activity in response to hypoxia. Transient 
transfection of PGM1 promoter deletion constructs found a hypoxia response to still occur 
within the (-135 to +101) region of PGM1 promoter. A manual search for potential HRE 
sequences within this region identified another potential HRE, located at (+19 to +23).  
Mutagenesis of this region however, showed no abrogation of PGM1 promoter activity in 
response to hypoxia. This suggests indirect effects of hypoxia and the hypoxia-mimicking 
agents (nickel II sulphate and cobalt II chloride) on PGM1 promoter activity, possibly through 
the binding of other transcription factors which may or may not be HIF-target genes such as 
metal-regulatory transcription factor 1 (MTF-1) or otherwise termed the metal-responsive-
element (MRE) binding transcription factor. MTF-1 is a pluripotent transcriptional regulator 
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involved in cellular adaptation to various stress conditions, primarily exposure to heavy 
metals but also to hypoxia or oxidative stress (Günther et al. 2012; Saydam et al. 2002). MTF-
1 has been shown to promote the cadmium-induced expression of N-myc downstream 
regulated gene (NDRG1). The exact molecular function of NDGR1 is unknown, however it has 
been shown to respond to several stress conditions and is often overexpressed in many types 
of cancer and the hypoxia-induced expression NDGR-1 has been established to be HIF1-
dependent (Bracher 2009). It is therefore likely that a similar mechanism could be applicable 
to the regulation of PGM1 under stress conditions, by both hypoxia and metal-induced stress 
which in our experimental model may obscure isolated hypoxic events.      
Together our data suggests that PGM1 expression is regulated by transcription factors such 
as E2F/DP1 and HIF1α. This regulation was observed in endogenous protein expression and 
at a transcriptional level as seen by alterations in mRNA expression and promoter activity. 
The regions in the PGM1 promoter responsible for E2F/DP1 and HIF1α regulation is however 
not clear at present as mutations of the putative binding sites had no effect on PGM1 










THE EFFECT OF PGM1 INHIBITION ON CANCER CELL METABOLISM AND 
BIOLOGY 
 
4.1 INTRODUCTION  
The immortalization and transformation of cells to attain a malignant phenotype is mostly 
driven by altered or abnormal gene expression patterns that consequently influence 
metabolic process in order to sustain tumour growth, viability and spread (Liu et al. 2010). 
Cancer cells are subject to fluctuations in extracellular conditions that often include periods 
of inadequate supply of energy sources such as glucose and glutamine, as well as oxygen. 
Nutrient availability is dependent upon an adequate blood supply to and within the growing 
tumour mass. In advanced solid tumours, oxygen delivery to the neoplastic and stromal cells 
is often reduced or even abolished by a diminishing diffusion gradient, structural 
abnormalities of tumour microvessels, and resultant disturbed microcirculation (Vaupel et al. 
1989). Irregularity in oxygen distribution causes changes in metabolic processes often driven 
by the activation of the transcription factor, HIF which promotes cancer cell survival and 
continued proliferation.    
The uptake, trafficking and conversion of glucose into energy, forms an integral part of the 
cancer’s response to the tumour microenvironment and these processes in cancer create a 
very unique metabolic profile directed by aberrant transcription factor activity.  
Recent studies have revealed a number of metabolic enzymes that show elevated expression 
and activity in cancer. Some of these enzymes have gained attention in the last decade as 
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potential therapeutic targets, with drugs targeting these enzymes being either under 
preclinical investigations or approved for clinical use (Vander Heiden 2011). Vander Heiden, 
(2011) makes a case for chemotherapy designed based on either targeting nucleotide, protein 
or lipid synthesis, amino acid, fatty acid, NAD or mitochondrial metabolism, glycolysis and the 
TCA cycle. 
In addition to the potential of individually targeting key molecules in metabolic pathways for 
cancer therapy, co-targeting metabolism along with traditional treatment regimens may help 
to overcome resistance to other cytotoxic agents by persistent cancer cells still stands. To 
exploit cancer metabolism and more rationally select complementary target combinations 
would require a thorough understanding of pathway biochemistry and metabolic regulation 
in cancer (Vander Heiden 2011). The basis of our investigations on the role PGM1 in cancer 
metabolism stem from its positioning in glucose metabolism. Much ambiguity still surrounds 
which pathways are preferentially supported by PGM1 activity due to the reversible nature 
of the enzyme. Our goal was to determine the following; which pathways; glycolysis, pentose 
phosphate pathway or glycogen synthesis are enhanced by PGM1 function and preferred by 
cancer cells when subjected to stresses commonly found in tumour settings such as 
hypoglycaemia and hypoxia. Secondly, to determine the biological significance of elevated 
PGM1 expression in cancer. 
As G6P, a direct product of PGM1 function in one direction, is a substrate for glycolysis, we 
investigate the effect of inhibiting PGM1 on glycolysis. Inhibition of glycolysis has been shown 
to effectively kill colon cancer cells and lymphoma cells in hypoxic environments in which the 
cancer cells exhibit high glycolytic activity and decreased sensitivity to common anticancer 
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agents (Xu et al. 2005). Furthermore, depletion of ATP through inhibition of glycolysis has also 
been shown to potently induce apoptosis in multidrug-resistant cells (Xu et al. 2005).  
G6P is also a substrate of the pentose phosphate pathway, a process that produces NADPH 
which is believed to contribute towards protecting cells from oxidative damage by scavenging 
ROS. This is particularly true for cancer cells where intracellular ROS levels may be higher due 
to excessively high proliferative rates (Tsouko et al. 2014). NADPH is also required for 
lipogenesis  supporting de novo synthesis of cell membranes (Perl et al. 2012). Somatic 
mutations resulting in oncogene activation and tumour suppressor inactivation are in part 
due to ROS produced as by-products of metabolism (Dang 2012).  
Glycogen is thought to provide an alternative source of energy for cancer cells under 
conditions of metabolic stress such as hypoxic and/or glucose depletion (Lee et al. 2004; 
Pescador et al. 2010; Pelletier et al. 2012; Favaro et al. 2012). We sought to determine 
whether PGM1 inhibition would influence the cells’ glycogen content, as excess G6P (that 
may accumulate via the action of hexokinases) can be converted to G1P by PGM1, after which, 
through a number of modifications, the modified UDP-glucose units are then linked up to 
construct glycogen polymer through the action of glycogen synthase 1 (GYS1). The 
synthesized glycogen can later be mobilized for energy in the event of a deficit in glucose 
entry from the extracellular environment.  
Jones & Thompson, (2009) stated that; “Growing tumours face two major metabolic 
challenges— how to meet the bioenergetic and biosynthetic demands of increased cell 
proliferation, and how to survive environmental fluctuations in external nutrient and oxygen 
availability when their growth outpaces the delivery capabilities of the existing vasculature”. 
The chronic and optimized use of glucose by cancer cells is thought to be means to tackle both 
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challenges. As a carbon source, glucose through accelerated glycolysis  can provide the ATP 
needed to sustain cellular functions and biosynthetic precursors to support cancer cell 
proliferation (Moreno-Sánchez et al. 2007; Sonveaux et al. 2012; Bao et al. 2013). Converting 
excess glucose into glycogen can also be an alternative source of energy in periods of 
prolonged nutrient deprivation. The metabolic fate of glucose involves three pathways, 
glycolysis, glycogen synthesis and the pentose phosphate pathway (Figure 4.0). PGM1 is 
located at a significant traffic point of glucose metabolism. 
In addition to monitoring metabolic pathways, whose function may be altered following 
PGM1 overexpression in cancer, the work done in this chapter also aimed to determine 
whether PGM1 inhibition affects cancer cell viability in the presence and absence of metabolic 



















Figure 4.0. The Fate of glucose through glycolysis, the pentose phosphate pathway and 
glycogen synthesis. PGM1 sits at a three-way of glucose metabolic pathways; glycolysis, the 
pentose phosphate pathway and glycogen metabolism. The arrows represent direction of 
glucose conversion through the different pathways to the metabolic outputs (indicated in 
black circles). In glycolysis (shown in green), glucose is converted to pyruvate through to 
lactate for energy, the entry of pyruvate into the mitochondrial to produce energy is often 
limited in cancer cells. In glycogen metabolism (shown in blue) G6P is converted to G1P, a 
precursor in glycogen synthesis, a product whose use is more pronounced when there is a 
deficit in extracellular glucose entry. In the pentose phosphate pathway (shown in red) G6P 
is converted to R5P, a precursor for nucleotide synthesis and NADPH used as an intracellular 





4.2 RESULTS  
4.2.1  The effect of PGM1 inhibition on glycogen content and glycolysis in cancer cells 
Our earlier results showed that PGM1 expression was high in cancer compared to normal cells 
in culture, and this was evident under both normoxic and hypoxic conditions. Here we aim to 
decipher the functional relevance of PGM1 in cancer cells by inhibiting its expression using 
siRNA. Western blot analysis shows successful and sustained inhibition of PGM1 in CaSki cells 
for up to four days post transection with targeted PGM1 siRNA in standard culture conditions 
of 25 mM glucose and normoxia (Figure 4.1). We performed a Periodic-Acid Schiff (PAS) stain 
for the presence of glycogen, where a pink stain indicated glycogen. Glycogen deposits were 
assayed in CaSki and HepG2 cells. Our results show that the inhibition of PGM1 in both cell 
lines causes a reduction in glycogen deposits in both cell lines (Figure 4.2). Accompanying 
western blots shows PGM1 knockdown at the same time points used to assay glycogen 
deposits. Glycogen content was assayed in HepG2 liver cancer cells as this cell line serves as 
a control for cells that should contain high glycogen levels as livers cell typically metabolize 
glucose into glycogen. These results were supported by the glycogen titration assay for 
quantitative analysis of glycogen stores. Our results show a significant reduction in glycogen 
content when PGM1 was inhibited in CaSki and HeLa cervical cancer cell lines (Figure 4.3). 
These observations were made in normal ambient culture conditions where oxygen 
availability and glucose are in excess, suggesting a role for PGM1 in glycogen metabolism in 
normoxia, in the absence of environmental stresses.  
Considering the role played by glycolysis in cancer cell survival and proliferation, we sought 
to investigate the effect of inhibiting PGM1 expression on glycolytic output by assaying lactate 
production, as lactate is a well-established end product of glycolysis in cancer cells (Holroyde 
82 
 
et al. 1979; Kennedy & Dewhirst 2010).  PGM1 converts G1P to G6P, and G6P through a series 
of reactions is converted to pyruvate which is then dehydrogenated to form lactate, and 
lactate is then secreted out of the cells into the extracellular environment where can be 
calorimetrically assayed.  
We inhibited PGM1 expression in cancer cells and investigated whether glycolysis would be 
affected in high (25mM, a concentration typically used for the culturing of most cancer cell 
lines) (Zhuang et al. 2014) and low glucose conditions (2.5 mM glucose which is approximately 
half of the physiological serum concentration of glucose) by assaying lactate levels. The 
rationale behind examining lactate production in hypoglycaemic conditions being that; 
mobilizing glycogen stores may be necessary to provide energy in the cells grown under 
conditions of extracellular glucose insufficiency and therefore PGM1 may be required to 
provide the G6P that is necessary for glycolysis in this context. Our results indicate that lactate 
production was significantly lower in CaSki cells cultured in low glucose (2.5 mM) compared 
to high glucose (25mM) (Figure 4.4). PGM1 inhibition resulted in a slight, but not significant 
decrease in lactate production in both conditions of glucose sufficiency (25 mM) and 
deprivation (2.5 mM).  The control cells and PGM1 knockdown cells displayed similar 
glycolytic output suggesting that PGM1, although participating in glycogen synthesis, it is not 
























Figure 4.1. Inhibition of PGM1 expression by targeted siRNA. CaSki cells were transfected 
with 20 nM control or PGM1 targeted siRNA and protein was harvested at 24, 48, 72 and 96 
hrs post transfection. Western Blot analysis showed significant reduction in PGM1 protein 
expression upon siRNA treatment. The scrambled (control) siRNA had no effect on PGM1 
protein levels. Western Blots shown are representative of experiments performed two 





Figure 4.2. PGM1 inhibition results in decreased glycogen content in cancer cells.  
Cells were cultured in media containing 25 mM glucose and transfected with scrambled 
Control siRNA and PGM1 siRNA over 96 hours then stained for glycogen using periodic acid 







Figure 4.3 Glycogen titration assay in CaSki and HeLa. Cells were cultured in media containing 
25 mM glucose and transfected with control siRNA and PGM1 siRNA for 96 hours followed by 
glycogen was extraction for assays. Experiments shown are the mean ± SD of experiments 
performed in triplicate and performed two independent times (* p < 0.05). Accompanying 



















Figure 4.4. Inhibition of PGM1 expression does not affect secreted lactate levels in high and 
low glucose. CaSki cells were plated in High (25 mM) and Low (2.5) glucose media, then 
treated with PGM1 siRNA for 72hrs, media was then collected from the cells and assayed for 
lactate. The glucose concentration influenced lactate output significantly, where the cells 
cultured low glucose showed reduced concentrations of lactate. Data shown are the mean 
±SD from three independent experiments *p < 0.05.  
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4.2.2  The effect of Inhibiting PGM1 expression in cancer cells on NADPH production, and 
intracellular ROS levels under ambient and metabolic stress conditions 
Evidence from previous studies comparing the production of ROS in cancer and normal cells 
suggests that cancer cells in general are under increased oxidative stress compared to normal 
cells (Szatrowski & Nathan 1991). Other studies have also gone further to show that 
neoplastic transformation is associated with increased basal oxidant stress (Trachootham et 
al. 2006). Cancer cells also have increased accumulation of ROS-mediated reaction products 
as well as the over-expression of antioxidant enzymes in response to oxidative stress (Pelicano 
et al. 2004), implying that the degree of oxidative stress in a cell hinges on the delicate the 
balance between the rate of ROS generation and the activity of scavenging systems that 
detoxify them (Schumacker 2006). NAPDH produced from the pentose-phosphate pathway 
proposed to have a role a one of detoxifying systems against ROS in cancer cells. As G6P (a 
product of PGM1 function), is as a substrate to the NADPH producing reaction catalysed by 
G6PDH, we assayed NADPH levels in control and PGM1 knockdown cells. We hypothesized 
that inhibiting PGM1 would result in a decrease in G6P and hence a decrease in NAPDH levels. 
Surprisingly, we observed an in increase NADPH in PGM1 knockdown cells grown in both high 
(Figure 4.5A) and low (Figure 4.5 B) glucose conditions. The difference was marginal in high 



















Figure 4.5. PGM1 inhibition significantly increased NADPH levels CaSki cells were cultured in 
A. 25 mM glucose and B. 2.5 mM glucose then transiently transfected with PGM1 siRNA and 
levels of NADPH were investigated 72 hrs post transfection using the NADPH assay (Abcam). 
A significant increase in NADPH levels when PGM1 was inhibited was observed. C. Western 
blots showing PGM1 inhibition, β-tubulin used as a loading control. Results the mean ± SEM 
of experiments performed in triplicate and repeated at least two independent times. * p<0.05   
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Since changes in NADPH levels influence general oxidative state of cells, we assayed global 
ROS levels in control and PGM1 knockdown cells. Inhibiting PGM1 had no effect on ROS 
production in conditions of low and high glucose (Figures 4.6 A and B).  Interestingly, when 
cells were exposed to hypoxia (1% oxygen in a hypoxic chamber), we observed hypoxia-
induced ROS production in both high and low glucose conditions (Figure 4.7 A), which is a 
documented result of exposure to oxygen deprivation (Kondoh et al. 2013). Despite these 
changes in ROS following hypoxic treatment, PGM1 knockdown did not influence the global 
ROS levels. The accompanying western blots show reduction in PGM1 expression PGM1 siRNA 
in all the conditions in cells tested (Figure 4.7 B). These results suggest that while PGM1 
influences NADPH levels these changes are not sufficient to lead to changes in ROS 






















Figure 4.6. PGM1 function does not influence the oxidative state of cancer cells. A. and B. 
CaSki and C. and D. HeLa cells grown in 25 mM (A and C) and 2.5 mM (B and D) glucose 
containing DMEM respectively and transiently transfected with control and PGM1 siRNA. All 
cells were then incubated with 25 μM DCF-DA for 30 min at 37℃ after fluorescence was 
measured every hour. ROS generation was measured by oxidation of DCF-DA. Western blot 
analysis was performed to verify inhibition of PGM1 expression in the experiment. No 
difference in ROS was observed in all conditions in response to PGM1 inhibition. Histograms 







Figure 4.7. PGM1 has no effect on hypoxia-induced ROS generation. A. CaSki cells were 
transfected with control and PGM1 siRNA for 72 hours, then incubated with 25 μM DCF-DA 
for 30 min after which cells were subjected to 1% oxygen for 2h30 min then assayed for ROS 
generation as a function of DCF-DA fluorescence. Results shown are the mean ±SD of 
experiments done in triplicate and performed at least two independent times, *p<0.05 
comparing normoxia and hypoxia. B. Protein lysates were harvested in parallel and run on a 




4.2.3 The effect of inhibiting PGM1 on cancer cell proliferation 
The effect of PGM1 inhibition on cancer cell proliferation was investigated by transiently 
inhibiting PGM1 expression using siRNA and assaying effects on proliferation in CaSki and 
HepG2 cells. Experiments were conducted in different media concentrations of glucose (25, 
10, 5 and 2.5 mM) as standard culturing media typically contains glucose levels that far exceed 
physiological serum concentrations (which is around 5.0 mmol/L) (Marín-Hernández et al. 
2011; Dubois et al. 2010). Our results show that inhibition of PGM1 had little effect on cell 
proliferation in all conditions (Figure 4.8 A-H) expect a marginal increase in proliferation 






Figure 4.8. PGM1 knockdown in cancer cells does not influence cell proliferation in physiological to 
high glucose levels. PGM1 expression was inhibited in A-D. CaSki cells and E-H. HepG2 cells using 
PGM1 targeted siRNA and a scrambled sequence was used as a control (ctrl). Effects on cell 
proliferation were assayed using of MTT assays in cells cultured in media containing 25, 10, 5 and 2.5 
mM glucose concentrations. Cells were transfected with Ctl and PGM1 siRNA, after 24 hrs re-plated 
into 96 well dishes containing media of different concentration. Accompanying western blots were 





We next inhibited PGM1 in conditions of oxygen deprivation and hypoglycaemia. These 
stresses go hand-in-hand in late-stage tumour presentation, thereby creating a simplified 
version of an in vitro mimic of the tumour microenvironment as described by Onozuka et al, 
(2011). Our results show that when cells encounter the double stress of low glucose and 
hypoxia PGM1 inhibition results in a reduction in cell proliferation within 24 hrs of hypoxia 
and low glucose. Our data suggest that under a combination of severe stress such as 





























Figure 4.9. Cell viability in low glucose (2.5 mM) and normoxia vs. hypoxia. A CaSki cells grown in 2.5 
mM glucose were subjected to treatment with 0.5 mM NiSO4to mimic hypoxia and proliferation was 
assayed. B Protein lysates were extracted 48 hours post transfect/24hrs after exposure to hypoxia 
mimicking agent. The Western blot below the bar charts was run to verify PGM1 inhibition in the 
experiment. Results are the mean ±SD of experiments performed in quadruplicate and repeated at 
least two independent times *p <0.05.  






Conditions in the extracellular environment of cancer cells or in vivo-tumour 
microenvironment are understood to be quite variable due to spatial challenges that often 
follow rapid cell proliferation and consequent expansion of the tumour mass. What is 
generally known and acknowledged is that the tumour microenvironment often experiences 
periods of hypoxia and hypoglycaemia and often acidic, a factor that has been largely 
attributed to the cancer cell’s preference for aerobic glycolysis that results in the production 
and excretion of lactate into the extracellular space.  
Our data, in agreement with current literature (Pelletier et al. 2012; Bae et al. 2014) shows 
that PGM1 inhibition results in reduced glycogen content in cancer cells. Our data using 
transient siRNA to inhibit PGM1 in cervical and liver cancer cell lines (CaSki, HeLa and HepG2 
cells) support the findings of Bae et al. (2014). The decrease in glycogen content was seen 
outside of hypoxic stress conditions and interestingly, the extracellular glucose concentration 
was sufficient to influence the levels of stored glycogen in cancer cells. Our results support 
the hypothesis that PGM1 is closely involved in the modulation of glycogen content in 
response to extracellular glucose levels. 
The question as to whether the stored glycogen proved beneficial for cancer cells in 
conditions of nutrient deprivation was addressed by looking at glycolytic output and effects 
on the pentose phosphate pathway. Our data showed that while glycogen content was 
directly influenced by PGM1 inhibition there was minimal effects on, glycolytic output as 
measured by lactate production. As the glucose concentration was decreased in the media, 
lactate production also declined but the presence or absence of PGM1 did not significantly 
influence yields regardless of the extracellular glucose concentration that the cells were 
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exposed to. It therefore seems that PGM1 function appears to mainly support glycogen 
synthesis, and not necessarily glycogen mobilization in this context, in contrast to findings 
done in yeast systems (Fu et al. 2000). Yeast systems have traditionally been extrapolated to 
have implications in cancer cells metabolism (Gururaj et al. 2004), however do not take into 
into account the impact of abnormal signalling that is often a feature of the cancer phenotype.  
We hypothesised that PGM1 could be enabling activities of the PPP, supporting 
macromolecular synthesis of lipids and nucleotides while also assisting in the scavenging ROS. 
Our data showed that PGM1 inhibition led to a significant increase in NADPH, particularly in 
hypoglycaemic conditions. This observation was surprising as we anticipated that inhibiting 
PGM1 would result in a decrease in NADPH levels. PGM1 inhibition led to a decrease in 
glycogen content, while having little effect on glycolysis. It is therefore conceivable that the 
remaining outlet for the glucose processing would be through flux into the pentose phosphate 
pathway and hence the subsequent increase in NADPH under low glucose conditions. Another 
explanation as to why NADPH production was increased in response to PGM1 inhibition is 
that NADPH is not only produced through the pentose phosphate pathway. Although the PPP 
plays as major part, other NADPH sources include the malic enzymes Me 1 and 2 as well as 
IDH (Jiang et al. 2014). Given the important role played by NADPH in maintaining cellular 
functions and its activity as a cofactor for many enzymes, breaking the balance between 
NADP+ and NADPH by blocking one or two of the pathways required to maintain this 
homeostasis would influence the activity of the others. It is possible that in our assay 
conditions, a compensatory effect between these NADPH-generating enzymes may be 
involved, as suggested by Jiang et al, (2014), in which NAPDH production via the malic 
enzymes and respond to the reduced outputs of the PPP due to depletion in hypoglycaemic 
stress in low glucose media. Our experimental design did not exclude or isolate out only the 
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NADPH produced via the PPP but assayed global NAPDH production making it likely that the 
other pathways could contribute towards NADPH production and even overcompensate for 
the limited outputs of PPP.  
An increase in NADPH production as literature would suggest, should yield increased 
macromolecular synthesis and reduced levels of ROS however, our data showed that while 
NADPH production increased in response to PGM1 knockdown, ROS levels were left 
unaffected irrespective of the extracellular environment. A possible reason to account for this 
observation may be that the changes in NADPH via the PPP were not sufficient to counteract 
or overcome the high levels of ROS. Hypoglycaemia stress would likely cause cells prioritize 
glucose metabolism via glycolysis over the PPP as the two process are co-ordinated together 
(Berg et al. 2002).  
Increased PGM1 expression was observed in late-stage cervical cancer specimens. A common 
characteristic of late stage cancer presentation is the emergence of hypoxic regions and a 
hypoglycaemic environment that is often associated with the insufficiency of the tumour 
vasculature. To find out whether cancer cells show a dependence on PGM1 for their survival 
and proliferation, we investigated responses to PGM1 inhibition in ambient and sufficient 
nutrient availability conditions as well as in sustained hypoglycaemic and hypoxic stress 
conditions. The proliferation of cells grown in high glucose was not affected by PGM1 
inhibition. This result was not surprizing as it is unlikely for cells to rely on glycogen content 
in an environment of glucose sufficiency. Bae et al, (2014) demonstrate that PGM1 inhibition 
did not show effects on cell number when cell were left to grow in 25 mM glucose. Reduced 
proliferative rates were only visible subsequent to a complete depletion of glucose in the 
culture media for 2 hrs followed by re-feeding of cells with 10 mM glucose (Bae et al. 2014). 
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The control cells were able to recover from the short-lived glucose deprivation while PGM1 
knockdown cells proliferated at a diminished rate. Our data, while complementing findings 
by Bae et al, (2014) in high glucose, showed that both CaSki and HepG2 cells were not affected 
by PGM1 knockdown in low glucose environments for prolonged periods. PGM1 knockdown 
cells grown in 10 to 2.5 mM glucose concentrations proliferated at comparable rates to the 
control cells, suggesting that PGM1 function was non-essential for survival under sustained 
hypoglycaemic stress. While both CaSki and HepG2 cells underwent cell proliferation in low 
glucose (2.5 mM) conditions, neither cell could survive and conditions of zero glucose (data 
not shown).    
When exposing cells to a combination of hypoglycaemic stress, and to a hypoxia mimicked 
environment, PGM1 knockdown cells showed significantly reduced proliferation. This could 
be explained by the fact that control cells treated with hypoxia can access their glycogen 
stores and even store up more glycogen in response to HIF signalling as reported by (Pelletier 
et al. 2012; Pescador et al. 2010; Favaro et al. 2012)). PGM1 knockdown cells on the other 
hand have had no access to stored glycogen in low glucose and hypoxia conditions. These 
findings support the theories demonstrating that cancer cells rely on their own intracellular 










5.1  MAIN CONCLUSIONS 
Altered metabolism as an additional hallmark of cancer cells  has been subject to much 
discussion in the past decade (Hanahan & Weinberg 2011; Ward & Thompson 2012). Cancer 
cells deregulate metabolic pathways as a means to maximize energy utilization and 
metabolite outputs to support biosynthetic processes occurring in highly proliferating cells 
(Vander Heiden et al. 2009). Differential expression patterns in metabolic gene expression 
have been observed in a number of cancers with links to clinical outcomes observed in a few, 
these include alterations in glucose metabolism which have been described and associated 
with cell survival  in cancers such as pancreatic and colorectal cancer (Cavalieri et al. 2007; 
Chaika et al. 2012; Gapstur et al. 2007).  
 
The targeting of metabolic pathways has shown promise in cancer therapy, and currently 
there are numerous small molecule inhibitors targeted against metabolic pathways under 
investigation as cancer therapeutic strategies. Evading metabolic blocks through bypass 
pathways and redundancy is possibly one of the major challenges to this approach to cancer 
treatment (Jones 2011). The need to understand key nodal points and possible combination 
strategies remains essential. Our interest in PGM1 stems from its position three-way of 
important pathways in glucose metabolism. Understanding this specific traffic point would 
bring insight into some of the metabolic priorities of cancer cells (Gururaj et al. 2004). 
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Our study is a first to show higher expression of PGM1 in cancer patient specimen compared 
to normal cervical biopsies. We also showed PGM1 expression to be high in cancer cell lines 
of other tissue origins compared to their normal counter parts, such as oesophageal cancer. 
Previous studies have shown a number genes involved in glucose management to have 
elevated expression in cancer, these include genes directly playing a part in glycolysis such as 
Phosphoglucose isomerase (PGI), Enolase 1 (Eno 1), Phosphoglycerate kinase 1 (PGK1) and 
Lactate dehydrogenase A (LDHA) (Tsutsumi et al. 2009; Capello et al. 2011; Chen et al. 2003; 
Ahmad et al. 2013; Billiard et al. 2013) and those participating in glycogen metabolism 
Glycogen Phosphorylase, muscle isoform (PYGL) and glycogen synthase (GYS) (Favaro et al. 
2012). The elevated expression of genes involved in glucose management of cancer cells 
confirms the significance metabolic pathways to cancer survival (Altenberg & Greulich 2004; 
Dang 2012). 
    
Through an analysis of the PGM1 promoter, we identified HIF1α and E2F proteins to be 
regulators of PGM1 transcription by directly binding to the PGM1 promoter and inducing 
expression. The DP1/E2F complex which is known to play a prominent role in cervical cancer 
development (Karstensen et al. 2006) was shown to influence PGM1 expression and directly 
bind to the PGM1 promoter at various regions. A recent study showed that E2F1 silenced 
oxidative metabolic gene expression and increased glycolytic gene expression, the 
predominant energy manufacturing pathway in cancer cells (Blanchet et al. 2013). Our data 
suggest a role for E2F/DP1 proteins in the control of glucose metabolism via PGM1 regulation.  
 
Under conditions of hypoxia we found PGM1 expression levels were significantly increased. 
Our data supports studies reporting an increase PGM1 expression in hypoxia with an 
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associated increase to glycogen accumulation (Pelletier et al. 2012; Favaro et al. 2012). Our 
study suggests that cancer cells already have higher PGM1 levels compared to normal which 
are further increased in hypoxia. Consequently, even without the introduction of hypoxia, 
glycogen levels were found to be significantly decreased following PGM1 inhibition. Our data 
showed increase PGM1 mRNA and protein expression and promoter activity in response to 
treatment with hypoxia mimicking agents. Reinforcing the idea that upregulation of PGM1 
under hypoxic conditions is a result of transcriptional events. PGM1 function is central to 
three metabolically significant pathways; glycolysis, glycogen synthesis and pentose 
phosphate pathway. HIF1α is known to have over a hundred target genes (Ke & Costa 2006) 
and many of these functioning in glucose management by these pathways under hypoxic 
conditions. In this study we show that HIF1α binds to the 5’UTR of the PGM1 gene supporting 
studies that have suggested an interaction between HIF1α and PGM1.     
 
We showed that PGM1 to have minimal effects on secreted lactate levels however, it was 
found to be integral to glycogen synthesis. PGM1 was also shown to influence the production 
of NADPH via the pentose phosphate pathway. Interestingly, cancer cell proliferation 
appeared unaffected in standard culture conditions (25 mM glucose and normoxia). However 
cancer cell viability was decreased following PGM1 inhibition with the introduction of a 
‘multiple-stress’ conditions of (hypoglycaemia and hypoxia), suggesting that PGM1’s role is to 
help cancer cells cope with conditions of severe stress while under amicable conditions its 
role is mainly in storing glycogen which can be released in periods of glucose deprivation and 
energy deficit (i.e., high ADP/ATP ratios). While we focused on the effects on cell viability seen 
under combined hypoglycaemic and hypoxic stress other studies have investigated the 
efficacy of cancer therapeutics that target metabolic targets under induced oxidative stress 
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conditions for example, and seen augmented drug sensitivity when cells were subjected to 
additional stress (Estan et al. 2014). A recent study reported that combined inhibition of 
glycolysis, the pentose cycle, and thioredoxin metabolism selectively increased cytotoxicity 
and oxidative stress in human breast and prostate cancer (Li et al. 2015). Many such 
investigations are underway that look at combined approaches to exploiting the unique 
features of the tumour microenvironment in cancer. These approaches selectively increase 
the environmental stress conditions within and around tumours based on the hypothesis that 
this will lead increased drug efficacy.   
 
5.2 SUMMARY OF KEY FINDINGS  
1. PGM1 expression is elevated in cervical, oesophageal and breast cancer cells 
2. Elevated PGM1 expression in cancer cells is as a result of increased transcriptional 
activation. 
3. PGM1 expression is elevated under conditions of hypoxia  
4. E2F and HIF1α are regulators of PGM1 expression. The exact regions in the PGM1 
promoter responsible for this regulation is not clear at present. 
5. PGM1 expression in cancer cells is required  for glycogen accumulation  
6. PGM1 is necessary for the proliferation of cancer cells under conditions of severe 








5.3  LIMITATIONS AND FURTHER DISCUSSIONS  
Our investigation were not without limitations, most of our experiments involving hypoxia 
were done in hypoxia-mimicked conditions, i.e., nickel sulphate or cobalt chloride treatments. 
While valuable information could be deducted and the experimental setting allowed for 
sustained inhibition of the prolyl hydroxylases that are responsible for HIF degradation, 
thereby HIF 1 expression and activity. We cannot discount other adverse effects that these 
agents may have had on cells apart from mimicking hypoxia. The ideal setting would be to 
perform hypoxia experiments in a hypoxic chamber designed for diverse experimental 
applications, particularly for tissue culture work, without a limited supply of nitrogen gas in 
order to maintain the oxygen potential. The hypoxic chamber used in some of these studies 
(chapter 4 for example) came with limitations such as those associated with the short half-
life of HIF proteins, making it difficult to sustain hypoxia and its responses for long enough to 
allow for downstream processing.  
There were difficulties also with interpreting promoter assays relative to the pTK-Renilla 
plasmid used as an internal control following other external treatments. This promoter 
showed increased activity in response to treatments with hypoxia mimicking agents as well 
as siRNA. To combat this limitation however, the pTK-Renilla control was used only where no 
further treatments were require and total protein used as an alternative where necessary. 
Recommended future work may include evaluating an approach in which glucose 
management is disrupted by blocking PGM1 expression and/or function while simultaneously 




There is often an inherent difficulty in replicating in vivo conditions in culture. This 
undoubtedly influences the accuracy of our assessments of cancer cell metabolism. In culture, 
cancer cells are ‘bathed’ in metabolic substrates (high glucose and the addition of glutamate) 
to support their proliferation and this would likely influence resultant metabolic programs 
(Papandreou et al. 2011). Recent studies contrasting responses to drugs such as 
Dichloroacetate (a drug that blocks glycolytic metabolism, and promotes mitochondrial 
respiration), in vitro versus in vivo, have seen modest effectiveness in killing cancer cells in 
culture while showing more dramatic cytotoxic effects in vivo (Chen et al. 2009). On this basis, 
possible future perspectives in this study could explore inhibiting PGM1 in xenograft mouse 















MATERIALS AND METHODS 
6.1 MATERIALS 
6.1.1 Cervical tissue specimen   
All cervical tissue specimen was obtained previously from Groote Schuur Hospital, 
Observatory, South Africa (Transcriptional Regulation and Cancer Biology Group, Medical 
biochemistry, UCT, RSA) upon consent from all patients involved in the study and the approval 
of the Research Ethics Committee of the University of Cape Town (REC REF153/2004). 
Cancerous tissue biopsies were collected from patients treated for cervical dysplasia and 
carcinoma, while non-cancerous (normal) tissue specimen were obtained from patients that 
were undergoing hysterectomies for reasons other than cervical cancer. A pathologist 
certified all specimen as either normal or diseased. RNA was previously isolated from the 
biopsies, genotyped and identified as HPV positive (Transcriptional Regulation and Cancer 
Biology Group, Medical biochemistry, UCT). 
6.1.2 Cell lines 
The cervical cancer cell lines; HeLa (HPV18), SiHa (HPV16), CaSki (HPV16 &18), Me180 (similar 
to HPV39), Ms751 (HPV18) and C33A (HPV negative) and the following normal and 
transformed fibroblasts; WI38 (normal lung) and its SV-40 transformed matched cell line, 
SVWI38 (transformed lung), CCD1068-SK (normal breast skin) as well as the non-tumorigenic 
breast epithelial cell line  MCF12A and breast cancer cell lines (T47D, MCF7 and MDA-MB-
231), were all obtained from the American Type Culture Collection (ATCC) (Rockville, MD, 
USA). All the above with the exception of MCF12 A cells were cultured under adherent 
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conditions at 37℃ in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with an 
antibiotic cocktail of penicillin (100 U/ml) and streptomycin (100µg/ml) with 10 % (v/v) heat-
inactivated Fetal Bovine Serum (FBS) (Gibco, Paisley, Scotland). Cells were cultured in a 5% 
CO2 conditioned humidified incubator and were routinely passaged every 2-3 days. MCF12A 
cells however, were maintained in media containing 50% Ham’s F12 media (Gibco) and 50% 
DMEM media with 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin 
with 20 ng/ml EGF (Gibco), 100 ng/ml Cholera toxin (Sigma, Aldrich, Germany), 500 ng/ml  
Hydrocortisone (Sigma) 10 µg/ml Insulin (Gibco).   
The primary cervical epithelial cells, HCX, were obtained from Drs. C Baker and A Baege at the 
National institute of Health, USA, the cells were cultured as described by Berger et al., 2002.  
Briefly, The HCX cells were retrieved from normal cervical tissue and kept in keratinocytes 
growth medium supplemented with EGF (10 ng/ml) and pituitary extract (50 µg/ml, cultured 
as described by van der Watt P et al., 2009 at 37°C, in an atmosphere of 95 % air and 5% CO2.  
The normal h-TERT-immortalized human oesophageal keratinocytes, EPC2 cells, were 
obtained as a gift from Prof A.K. Rustgi (University of Pennsylvania, Philadelphia, USA). FGo 
normal skin fibroblasts were acquired from the Department of Medicine, UCT, and 
transformed fibroblasts, CT1 as referred to in Namba et al., 1980. Oesophageal carcinoma cell 
line, WHCO1 cell line was established from a South African patient with oesophageal 
squamous cell carcinoma, and obtained as a gift from Dr R. Veale. Oesophageal carcinoma 
cell lines, KYSE30, 70, 150, 180 and 450, were obtained from DSMZ (Berlin, Germany).    The 
epithelial liver cancer cells, HepG2, were acquired from the UCT Heart foundation and 
cultured adherently in antibiotic free, DMEM and 10% (v/v) non-heat-inactivated FBS. All cell 
lines were kept in a 5% CO2 humidified incubator and routinely passaged every 2-4 days.  
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6.1.3 siRNA  
For the inhibition of gene expression, short-interfering RNA (siRNA) was used; PGM1 siRNA 
(ID: s10407) (Ambion-Life technologies, California, USA) and p53 siRNA (sc-29435), DP1 siRNA 
(sc-37813), Santa Cruz Biotechnology, Santa Cruz, CA, USA). Control siRNA-A consisting of a 
scrambled sequence (sc-37007, Santa Cruz Biotechnology) was used as a non-silencing 
control. siRNAs were provided as lyophilised powders and were reconstituted in nuclease-
free water to give a stock concentration of 10 µM. E7 siRNA was designed as described by 
Tang et al., 2006. RNA oligos were synthesised by Ella Biotech GmBH (Germany) and annealed 
in a reaction containing 30 µl each RNA oligo (50 µM) and 15 µl annealing buffer (100 mM 
Potassium acetate, 20 mM Hepes, pH 7.4, 2 mM Magnesium acetate) at 90°C for 1 minute, 
followed by 37°C for 1 hour, to give a final siRNA concentration of 20 µM. 
 
6.1.4 2', 7'-Dichlorodihydrofluorescein Diacetate (H2DCFDA) 
H2DCFDA is a cell-permeable non-fluorescent probe used for quantitation of reactive oxygen 
species (ROS) was obtained from Sigma (Aldrich, Germany). ROS was measured in response 
to PGM1 inhibition in different extracellular environments. Kept as 50 mM stock, dissolved in 







6.1.5 Hypoxia mimics: Nickel Sulphate (II) and Cobalt (II) Chloride  
Hypoxia mimicking agents which function by attenuating activity of prolyl hydroxylases 
therefore rendering HIF active to bind to its target genes as would be in hypoxia. These were 
obtained from Sigma, kept at a stock concentration of 0.25 M and stored at -20 °C. 
6.1.6 Actinomycin D 
A polypeptide antibiotic, obtained from Sigma (Aldrich, Germany) used as an inhibitor of de 
novo transcription, was dissolved in DMSO and kept at -80 °C at a concentration of 400 µg/ml.     
6.1.7 Plasmids  
The pGEM-T Easy plasmid (Promega, Madison, WI, USA) was used as a tool for sub-cloning 
PCR products of the PGM1 promoter region. The pGL3-Basic reporter plasmid (Promega) was 
used for the cloning of sequence-confirmed promoter fragments upstream of a luciferase 
construct. pRL-TK (Promega) encoding the Renilla reporter gene was used to normalize for 
transfection efficiency unless otherwise specified. To assay for the effect of Rb overexpression 
on PGM1 promoter activity, cells were co-transfected with 400 ng pCMV or RcCMV/Rb 
(Addgene plasmid 1763, provided by Bob Weinberg).  
 
6.2 Methods  
 6.2.1 Quantitative real time PCR (qRTPCR) 
To validate microarray data in cervical tissue specimen and investigate differential gene 
expression in cells, qRTPCR was employed. For patient specimen, RNA was previously 
extracted from normal and cervical cancer patient tissue samples using the Trizol reagent 
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(phenol/guanidine isothiocyanate) (Invitrogen, Rockville, MD, USA), according to the 
manufacturer’s instructions, van der Watt et al., 2009. First strand cDNA was then synthesized 
in following manner; 2 µg of RNA was used as template and mixed with T7 oligo dT primers 
per sample then reverse transcribed in 20 µl reaction consisting of 1 µl ImPromII Reverse 
Transcriptase II (Promega), 1 µl RNAsin (Promega), 2 mM MgCl2, 1 mM dNTPs and 1 X 
ImPromII reaction buffer (Promega). Quantitative real time RT-PCR was done using a Step One 
Instrument according to the manufacture’s operator’s manual (Applied Biosystems, CA, USA). 
A master mix was prepared containing nuclease free water, Kapa SyBr green fast (Kapa 
Biosystems), a pair of forward and reverse primers (refer to the Table 6.1 below) in separate 
master mixes for each target gene and housekeeping genes. For patient cDNA β-
glucuronidase (Gus B) and Cyclophilin D Ct values were averaged used as a single reference 
value to normalize data. 2 µl of synthesised cDNA was used as a template for the qRTPCR 
reaction.      





PGM1 Forward 5’-ATGATTACGAGGAGGTGGAAG-3’ 
150 55 
PGM1 Reverse 5’-CTGGGTCGCTGTATTCAAAG-3’ 
PGK1 Forward 5’-AAGAAGTATGCTGAGGCTGTC-3’ 
150 55 
PGK1 Reverse 5’-GCAAGTGGCAGTGTCTCC-3’ 
VEGF A Forward 5-TTCATGGATGTCTATCAGCG-3’ 
236 60 
VEGF A Reverse 5’-GCTCATCTCTCCTATGTGCT-3’ 
Enolase 1 Forward 5’-GCCGTGAACGAGAAGTCC-3’ 150 55 
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Enolase 1 Reverse 5’-CAGGTCAGCGATGAAGGTATC-3’ 
Cyclophilin D Forward 5’-TGAGACAGCAGATAGAGCCAAGC-3’ 
94 60 
Cyclophilin D Reverse 5’-TCCCTGCCAATTTGACATCTTC-3’ 
GusB Forward 5’-CTCATTTGGAATTTTGCCGATT-3’ 
81 55 
GusB Reverse 5’-CCGAGTGAAGATCCCCTTTTTA-3’ 
B-Actin Forward  5’-ATCGTGCGTGACATTAAGGA-3’ 
178 60 
B-Actin Reverse 5’-AGGAAGGAAGGCTGGAAGAG-3’ 
Ta being the annealing temperature used in the cycling stages of the real-time PCR reaction 
6.2.2 Western blot analysis   
Media was removed and cells were washed twice in ice cold 1X PBS. A fresh mixture of 10 X 
complete protease inhibitor cocktail (Roche, Basel, Switzerland) was added to RIPA lysis 
buffer as well as phosphatase inhibitor (0.1 M Sodium validate). The mixture was then added 
to cells and lysates were collected by scraping using a rubber police man. The protein lysate 
was separated from debris by centrifugation and protein concentrations were determined 
using the BCA protein assay kit (Thermo Fisher Scientific Pierce, Illinois, USA). The protein 
molecular weight marker, Spectra-BR (Thermo Fisher Scientific Fermentas, Illinois, USA) for 
the determination of protein size.  20-30 µg of total protein was loaded onto SDS 
Polyacrylamide gels prepared according to (Table 6.2) and ran at 185 V for 1 h. Protein was 
then transferred to a HybondTM –ECL TM nitrocellulose membrane (Amersham Biosciences, 
Buckinghamshire, UK) at 100 V, for 1 hour. Membranes were blocked for either 1 hour with 
shaking at room temperature or overnight at 4⁰C in 5 % milk (in TBST) and incubated in 
primary and secondary antibodies according to the conditions indicated in (Table 6.3) below. 
Detection of bands was done by chemiluminescence, using Lumiglo or Lumiglo Reserve (KPL 
112 
 
Inc., Gaithersburg, MD, USA), depending on the strength of the signal. In detection of different 
antibodies on the same blot, the membranes were stripped in 1 M Glycine, pH 2.5 for 5 
minutes then neutralised with 1/10 volume 1 M Tris-Cl, pH 7.5. The membranes were then 
washed four times with TBST after which blocking and re-probing with the primary antibody 
could proceed. 




Resolving Gel Solution 10% 
(1.5 mm gel) 
7.5 % 
(1.5 mm gel 
15% 
(1.5 mm gel) 
Resolving gel buffer 3 ml 3 ml 3 ml 
30 % Acrylamide  3ml 2.25 ml 4.5 ml 
dH2O 3ml 3.75 ml 1.5 ml 
10 % Ammonium Persulphate (APS) 180 µl 180 µl 180 µl 
TEMED 18 µl 18 µl 18 µl 
Stacking Gel Solution 1.5 mm gel 1 mm gel  
Stacking gel buffer 1.5 ml 750 µl   
30 % Acrylamide 1 ml 500 µl  
dH2O 3.5 ml 1.75 ml  
10% APS 60 µl 30 µl  
TEMED 6 µl 3 µl  
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[Sc-601, Santa Cruz 
Biotechnology] 






Phospho-RB (Ser 807/811) 
[9308S, Cell Signalling] 
1:500 in 5% 
BSA (in TBST) 
Goat anti-rabbit 
[Bio-rad]  




[sc-13515, Santa Cruz 
Biotechnology] 
1: 500 in 2.5 % 
milk (in TBST) 
Goat anti-mouse  
[Bio-rad] 




[sc-9104, Santa Cruz 
Biotechnology] 

















p21 (H-164)                               
[sc-756, Santa Cruz 
Biotechnology] 
1:250 in 2.5 % 







       
6.2.3 Immunofluorescence  
Cells were cultured on cover-slips then washed 3 x 5 minutes each in 1 x PBS and then fixed 
in 4% paraformaldehyde in PBS. They were then permeabilized using 0.5 % Triton X 100 in 
PBS for 5 minutes. The cells were washed again in PBS and quenched in 50mM NH4Cl in PBS 
for 5minutes. NH4Cl was removed and the cells were blocked for 30 min in 0.2% gelatine. 
After blocking, the cover slips were removed from culture dishes and inverted on to primary 
antibody: mouse anti-PGM1 [1:100 in 0.2 % gelatine], the cover-slips were incubated at room 
temperature in a humidified chamber for 45 minutes, then washed in PBS for 3 x 5 minutes 
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and then incubated in secondary antibody: Alexa 488-conjugated donkey anti-mouse [1:200 
in 0.2 % gelatine] for 45 minutes in a humidified chamber and washed again. The nuclei of 
cells were stained with DAPI (at 100 ng/ml) and cover slips were washed again in PBS and 
mounted on slides in mowiol. Slides were allowed to dry in the dark and fluorescence was 
visualised by standard fluorescence microscopy using a Zeiss Axiovert 200M fluorescence 
microscope with optical filters that were used for the separate imaging of Alexa 488 and DAPI 
signals. Images were analysed by selecting regions of equal size using an interactive graphics 
screen as a feature of the AxioVision Release 4.5 software.         
 
6.2.4 Transfections with siRNA  
Cells were plated in 35 mm dishes or 60 mm dishes at a concentration of 150 000-200 000 
cells or 400 000-500 000 cells per dish respectively. The next day a transfection mixture was 
prepared using DMEM (Gibco) media free of antibiotics and fetal calf serum (FCS), transfectin 
lipid reagent (biorad) 0.625 µl or 1.25 µl for 35 mm or 60 mmm dishes respectively and added 
to the above media and left for five minutes after which siRNA was added. For control dishes 
a scrambled sequence siRNA, control siRNA-A (Santa Cruz) was used to treat cells, the mixture 
was left for 15 to 20 minutes after which it was added drop-wise to cells suspended in 1 ml 
DMEM with 10% FCS for 35 mm dishes and 2 ml media when 60 mm dishes were used making 
up a final siRNA concentration of 20 nM in each dish. Cells were left to incubate for either 6 
hours or overnight in siRNA containing media. The Media was removed and replaced with 
normal complete media (DMEM, 10% FCS and Penicillin and streptomycin antibiotics). Effect 
of treatment with targeting siRNA was then investigated and knockdown was validated by 
western blotting or qRT-PCR. 
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6.2.5 Cell Proliferation assays 
Cells were transfected according to the above transfection protocol and counted for plating 
2000 cells/well in a 96 well plate. After plating a tetrazolium salt, MTT (3–(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)(Sigma), was added to cells which was 
metabolised by the active mitochondria of live cells to a purple formazan dye. Solubilisation 
reagent consisting largely of sodium duodecyl sulphate (SDS) (Merck, Darmstadt, Germany), 
was added to cells 4 hours later to lyse the cells releasing the dye. Samples were then left 
overnight to create a homogenous solution and an absorbance reading was taken at 595 nm 
on a calorimetric plate reader (BioTek, Winooski, VT, USA) and related to the amount of cells. 
Cells treated with control siRNA and PGM1 targeting siRNA were compared in terms of their 
rate of proliferation over 5 or 6 days.     
6.2.6 Periodic Acid Schiff (PAS) assay 
Cells were plated at 150 000 cells/dish in 35 mm dishes on cover slips for the PAS experiment 
and without cover slips for protein extractions. The next day they were transfected with 
control (scrambled) siRNA and PGM1 siRNA. 72 hrs post transfection the PAS experiment was 
conducted as follows: 
Cells were washed thrice with ice-cold PBS, the cells fixed in methanol at 20℃ for 5 min. 
Methanol was removed and cells were immersed in freshly made-up Periodic acid (Merck) 1% 
(w/v) in 70 % ethanol for 30 min a room temperature. The cells were then rinsed twice with 
water and consequently stained with Schiff’s reagent (Merck) for 5 min at room temperature 
then rinsed continually for at least 30 minutes. 
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To mount coverslips on slides, cells were dehydrated by immersing coverslips in different 
concentrations of ethanol, 70% and 96% respectively once and absolute alcohol twice, then 
in Xylene twice. The cells were then mounted in non-aqueous mounting fluid Entellan (Merck) 
and viewed under a bright-field microscope for glycogen staining.  
6.2.7 Glycogen titration assay 
To quantitatively determine the levels of glycogen after inhibition PGM1 expression, the 
glycogen assay was employed using the Glycogen Assay Kit (Abcam) according to the 
manufactures instructions. Cells were grown in 25 mM glucose containing DMEM media and 
transfected for 72 hrs with PGM1 targeted siRNA, cells transfected with scrambled siRNA 
were used as a control. The same cells were then transfected again for 96 hours. Cells were 
washed twice in ice cold PBS to remove all glucose and harvested in 200 µl dH2O.  Samples 
were then boiled for 5 minutes to inactivate enzymes and centrifuged at 14000 xg. The 
supernatant was then kept for further processing. Glycogen samples were then subjected to 
hydrolysis using gluco-amylase in hydrolysis buffer to obtain the total amount of released 
glucose. A sample containing no enzyme was used to control for free background glucose. 
The released glucose from the glycogen hydrolysis reaction was then oxidized in a 
development reaction to produce a detectable product with an OxiRed probe. The coloured 
product from this reaction was then measured calorimetrically at 570 nm. The glycogen 
content of the sample was calculated by subtracting free background glucose present in 
samples prior to hydrolysis and normalized to protein concentration.  
6.2.8 NADPH assay  
The assay to determine levels of NADPH was employed using the NADP/NADPH assay kit- 
ab6534, according to the manufacturer’s instructions (Abcam, Cambridge, UK). Briefly 
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samples are prepared as follows: Cells are plated in 60 mm dishes and transfected with siRNA 
over 72 hours, the cells (approx. 105 cells) are then washed in PBS to remove media and 
trypsinized and re-suspended in extraction buffer 200µl. The lysate was then homogenised 
by sonicating for 30 seconds on ice. Samples were then heat treated (by heating samples on 
a heating block at 60⁰C for 30 min) to eliminate the any NADP present in the sample on order 
to quantitate only NADPH. NADPH standard stock solution of 1 nmol/µl is diluted in 
NADP/NADPH extraction buffer to create a concentration series in duplicate of 0, 20, 40, 60, 
80 and 100pmol/µl. The extracted cell lysate was diluted in 1:3 in NADP/NADPH extraction 
buffer in duplicate in a 96 well plate. NADP cycling enzyme was added to standards and 
samples and left to incubate for 5min, then NADPH developer was added to the sample 
mixtures. The reaction was allowed to develop for 3 hours at least with OD reading taken at 
450 nm after every hour. The concentration NADPH in each sample was determined using the 
standard curve. 
6.2.9 ROS assays  
To investigate the effect of PGM1 inhibition on intracellular ROS generation in low (2.5 mM 
glucose containing media), high (25 mM glucose containing media) normoxia and hypoxic 
conditions, the cell-permeant 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) (also 
known as dichlorofluorescin diacetate) was used. H2DCFDA is a chemically reduced form of 
fluorescein used as an indicator for reactive oxygen species (ROS) in cells. Briefly, 10 000 
cells/well were plated in white, sterile flat bottom 96 well plates in media containing 2.5 or 
25 mM glucose. The next day cells were transfect with control or PGM1 siRNA, then the next 
day an additional 100 µl of media (2.5 or 25 mm glucose containing media) was added to 
neutralize the transfection reagent and prevent dehydration. Cells were left for 48 hours and 
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then assayed for ROS generation, 72hrs post transfection in normoxia. In hypoxia however, 
before staining cells with H2DCFDA, plates were incubated for 2h30 in a hypoxic chamber (1% 
oxygen and 98.8% Nitrogen).  Alternatively for hypoxia treatments with hypoxia mimicking 
compounds (i.e. Nickel 0.5 mM Nickel (II) Sulphate), cell were left instead for 24 hours post 
transfection and the next day subjected to NiSO4 treatment for 24 hrs. 72 hrs post 
transfection with siRNA, media was removed and cells were washed once with 100 µl pre-
warmed (37⁰C) Krebs ringer buffer then treated with 25 µM H2DCFDA in Krebs ringer buffer 
for 30 min in the dark after which fluorescence was read at Ex:485 nm and Em: 530 nm. 
Treatment with 5 µM Doxorubicin at different time points (15 min, 30 min, 1, 2, 3 and 4 hours) 
was done concurrently as a positive control and unstained cells were set aside as a negative 
control for background fluorescence.  
6.2.10 PCR amplification of the PGM1 (-1988 to +101) promoter  
In order to retrieve the DNA fragment consisting of the 5’-regulatory region of PGM1 to 
investigate PGM1 promoter activity in cells, PCR primers to amplify the region approximately 
2 kb upstream and 100 bp downstream of the PGM1 transcription start site (TSS) were 
designed using Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) based on 
the sequence information in GenBank (accession number NC_000001.10). The primers were 
designed to incorporate restriction enzyme sites flanking either end with the forward primer 
containing the NheI site (G^CTAGC) and the reverse primer with a HindIII site (A^AGCTT) 
respectively for cloning into a pGL3-Basic vector. Importantly the restriction enzyme sites 
selected for the primer design had to be absent in the promoter insert but and the pGEMT-
easy shuttle vector but only present in multiple cloning site of the pGL3-Basic vector. On each 
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primer, an extra two based was added on the 5’-end of each restriction enzyme site in order 
to aid with binding. Sequences and positions of the primers are shown in (Table 6.4).  
The PCR reaction as performed using 100 ng genomic DNA from normal blood as the template 
in 5 µl of 10 X PFU Buffer, 1.25 µl each of 20 µM primers (Forward and Reverse), 1 µl 10 mM 
dNTPs, 2.5 µl of 5% DMSO and 3µl of 25 mM MgCl2 added to reduce non-specific binding with 
0.5 µl of the high fidelity enzyme PFU DNA polymerase (Fermentas, Thermo Fischer Scientific, 
Waltham, MA, USA) to minimize PCR errors and filled up with nuclease-free water to make 
up a 50 µl reaction. The conditions used for the PCR reaction were initially denaturation at 
95°C for 5 min, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 
30s, and extension at 72°C for 3 min, with the final extension at 72°C for 15 mi to allow for 
the amplification of lengthy DNA fragments. However due to difficulty in seeing a clear and 
precise PCR product, the PCR reaction was optimized by setting up gradient PCR experiment 
in which the annealing temperature is ramped from 55 to 65.1°C. 63.4°C was found to be the 
optimal annealing temperature for amplification of the correct product.  









PGM1 F 5’ AGGCTAGCGGCCACAGTAACCCTGTCCAGA  3’ -1988 to -1966 
2089 63.4 
PGM1 R 5’ AGAAGCTTACTCTAGGCCGGCGTTTGGC 3’ +81 to +101 
The NheI site is in bold and the HindIII site is underlined. The position of the primers 
represents the matching sequence in the 5’-regulatory region of the PGM1 gene, not including 
the added restriction sites and extra bases, and therefore not represent the exact size of the 
primer. The relative positioning is based on numbering the first base of the transcription start 
site as +1, with upstream sequences indicated as negative numbers. Ta being the annealing 




6.2.11 PCR products purification and A-tailing for cloning the promoter into pGEM-T Easy 
The products from the PCR reaction were run on a 1 % agarose gel and visualized using 
ethidium bromide and UV. The PCR product bands were then excised from the gel using a 
sharp blade and the DNA was cleaned up using the Wizard SV gel and PCR Clean-up System 
(Promega) according to the manufacturer’s instructions. The cleaned up PCR products were 
then A-tailed using 5 U Taq polymerase (Stratagene) in a reaction containing 1X Taq buffer, 
2.5 mM MgCl2 and 0.2 mM dATP in a total volume of 10 µl incubated at 70°C for 30 min. This 
was done because the Taq polymerase enzyme yielded blunt ends, therefore A-tailing was 
necessary to facilitate the PCR product ligation into the pGEM-T Easy plasmid.  
 
6.2.12  Sub-cloning of PGM1 promoter PCR products into pGEM-T Easy 
A ligation reaction was then set up and incubated overnight at 4°C consisting of 3µl of the A-
tailed promoter PCR product and 50 ng pGEM-T Easy in 5µl of 2 X Rapid ligation buffer and 3 
U/µl of T4 DNA-Ligase (Promega) in a total volume of 10 µl. Half of the ligated plasmid 
preparation was then used to transform 30 µl competent JM109 cells (Promega) for 20 min 
on ice. The bacterial cells were then heat-shocked at 42°C for 2 min to facilitate uptake of the 
plasmid DNA and placed back on ice for another 2 min. 450 µl of LB broth was then added to 
the mix and incubated at 37°C for 1 hr, after which 100 µl and 400µl were spread on separate 
agar plates containing 100 µg/ml Ampicillin, and onto which 100 µl 0.1 M IPTG and 20 µl 50 





6.2.13 Preparation of recombinant pGEM-T Easy clones for screening of correct inserts 
White colonies were then selected for screening. Representative colonies were pick 
inoculated from the agar plate into 5 ml Luria broth (LB) and incubated at 37°C, overnight 
with shaking at 200 rpm.  The next day glycerol stocks were made by mixing 500 µl of bacterial 
culture with 500 µl of sterile 80% glycerol. Glycerol stocks were then kept at -80°C for long-
term storage. The remaining 4 ml of the bacterial culture was then used to extracted plasmid 
DNA using a Pure-Yield Mini-prep System (Promega). The 4 ml culture was split into two 2 ml 
epperndorf tubes then span down to collect the cells. The supernatant was discard and the 
pellets re-suspended in 600 µl of water. The suspension was then lysed in a blue Cell Lysis 
Buffer and neutralized using a Neutralizing solution after which the mixture was centrifuged 
at maximum speed using a small bench-top centrifuge (or microcentrifuge) at room 
temperature for 3 minutes. The supernatant (~900µl) was transferred to a PureYield 
Minicolumn without disturbing the cell debris pellet. After spinning for 15 sec the flowthrough 
was discarded and endotoxins were removed by washing the cells with 200µl and again with 
400µl of Column Wash Solution. DNA was eluted in 30µl of nuclease-free water, and plasmid 
stored at –20°C. The correct clones were identified from false positives, by doing a restriction 
enzyme double digested using 5 U Nhe I and 5 U HindIII (both from Promega) in 1x Buffer B 
and 0.5 µg DNA, overnight at 37°C. Digests were then run alongside uncut plasmid on a 1 % 
agarose gel. Positive clones were then selected for downstream experiments.    
6.2.14 Preparation and large scale retrieval of high quality pGEM-T Easy recombinant 
clones with the 2kb PGM1 promoter fragment for sequencing.  
A large-scale retrieval of high quality recombinant pGEM-T Easy clones containing the PGM1 
5’-regulatory region was performed using the Qiagen Maxi-prep. Bacterial cultures were first 
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grown up from glycerol stocks by inoculating into 5 ml LB containing 60 µg/ml Ampicillin and 
incubated for approximately 4 hrs at 37°C with shaking at 200 rpm to make up a starter culture 
which was then transferred into 100 ml LB containing 100 µg/ml Ampicillin and incubated for 
overnight (approximately 16 hrs) at 37°C with shaking at 200 rpm.  
Bacterial cultures were then span down at 6000 rpm, supernatant discarded and pellet re-
suspended in Buffer P1 containing 100 µg/ml RNAse. The re-suspension was lysed in Buffer 
P2 for 5 minutes at room temperature, and the solution was then neutralised using Buffer P3 
for 20 minutes on ice. The supernatant was isolated by centrifugation at 13000 rpm for 30 
minutes, followed by an additional centrifugation step for 15 minutes to ensure complete 
exclusion of the suspended material (containing genomic DNA, proteins and cell debris), the 
supernatant was applied to a Qiagen-tip according to the manufacturer’s instructions. After 
several washes, the eluate was precipitated using 0.7 volumes isopropanol and centrifuged. 
The DNA pellet was then washed with 70 % Ethanol and then air-dried and re-suspended in 
50 µl TE buffer, pH 8.0. The plasmids were cut with NheI and HindIII restriction enzymes, and 
electrophoresed to verify the isolation of the correct plasmids.     
6.2.15 Sequence confirmation to verify correct PGM1 promoter insert 
To confirm the correct sequence of the PGM1 promoter within the pGEM-T Easy plasmid 
vector, sequencing reactions were performed using the BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems), according to the manufacturer’s instructions. Reactions 
were set up using the primers in (Table 6.5). (2 mM primer solution was made up from a 20 
mM stock of primers) with 6.4 ρmol sequencing primer and 0.5 µg template plasmid DNA was 
used in each sequencing reaction. The following cycling conditions were used: 96°C for 1 
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minute, followed by 25 cycles of 96°C for 10 seconds, 45 °C for 5 seconds, and 60°C for 4 
minutes.      





T7 primer 5’ TAATACGACTCACTATAGGG 3’ In pGEM-T Easy 45 
SP6 primer 5’ CGATTTAGGTGACACTATAG 3’ In pGEM-T Easy 45 
PGM1 seq primer 1 (F) 5’ GGTAATGATATGCTCTGG 3’ -758 to -740 45 
Ta refers to the annealing temperature used in the cycling stages of the PCR. 
6.2.16 Cloning of PGM1 promoter upstream of the luciferase construct in pGl3-Basic 
10µg of recombinant pGEM-T Easy constructs containing the sequence verified PGM1 
promoter fragments were digested with the restriction enzymes NheI and HindIII to release 
the cloned inserts and 5 µg of the pGL3-Basic vector was digested with the same enzymes to 
linearize the vectors. Digest were then run on a 1% agarose gel at 80 V for 2 hours, the 
released inserts and linearized pGL3-Basic vector were then excised from the gel and cleaned 
up using the Wizard SV gel and PCR Clean-up System (Promega) according to the 
manufacturer’s instructions.  
The amount of insert DNA to be used for ligation was determined using the equation:  
ng vector/Kb vector x Kb insert x molar ratio (insert:vector) = ng insert 
(where 100 ng vector DNA was used, and an insert:vector ratio of 2.5:1). 
 
The cleaned up linearized vector and promoter inserts were then quantified and ligated using 
T4-DNALigase (Fermentas) in a reaction containing 10 X ligation buffer (Fermentas) 10 % 
polyethylene glycol (PEG) to facilitate the ligation reaction, 100 ng of plasmid and 250 ng of 
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insert, filled up with water to 10 µl. The ligation was done at 4°C overnight (± 16 hrs). The 
entire ligation reaction mix was used to transform 40 µl of competent JM109 cells as 
described previously in Section 6.2.14. The next day colonies were picked and screened for 
the correct insert. Positive clones were identified by restriction digestion analysis and grown 
up for large-scale plasmid preparations as described in Section 6.2.16. 
6.2.17 Luciferase assays 
400 ng of each promoter construct was transfected into 300 000 CaSki cervical cancer 
cells/well of a 6-well plate, using 1.2 µl Transfectin (Bio-Rad) (i.e. the DNA (µg) to Transfectin 
(µl) ratio was 1:3). The pRL-TK plasmid (that encodes Renilla luciferase) along with the 
promoter constructs was used normalise for transfection efficiency, cells were co-transfected 
with 50 ng Renilla plasmid. In the case of cells that were treated with hypoxia mimicking 
agents following transfection, based on the effect of hypoxia on the pRL-TK Renilla plasmid 
luciferase readings were normalized to protein concentration instead. Transfection mixes 
were made up in 100 µl serum-free, p/s-free DMEM and after a 20 minute incubation, added 
drop-wise to the cells in 1 ml media (containing 10 % FCS and p/s). 24 hours post transfection, 
media was removed from cells. Cells were washed with 1x PBS and total cell lysates were 
extracted from cells in 200 µl of 0.25 mM Tris, pH 8.0, and firefly luciferase activity was 
assayed using the Dual Luciferase Kit (Promega). Luminescence was monitored using the 
Glomax 96 microplate luminometer (Promega). Promoter activity was normalised to the 





6.2.18 Rb overexpression  
To assay for the effect of Rb overexpression on PGM1 promoter activities, cells were co-
transfected with 400 ng pCMV or RcCMV/Rb (Addgene plasmid 1763, provided by Bob 
Weinberg),  400ng pGL3-pPGM1 (-1988/+101) construct and 50 ng Renilla, using 2.4 µl 
Transfectin per well in a 6 well plate. Cells were incubated for 48 hours after transfection, 
and luciferase assays performed. 
 
6.2.19 Generating deletion constructs  
PGM1 promoter deletion constructs were generated using gene-specific forward primers with 
a Nhe I restriction site incorporated into each respective primer shown in (Table 6.6) to create 
the promoter fragments shown in (Figure 6.1), and PGM1 R (containing the HindIII site) was 
used as the reverse primer. A PCR was done using the cloned pGL3-Basic constructs described 
previously as the template DNA. The PCR products were purified and cloned into the pGL3-
Basic vector to generate shorter constructs of the PGM1 promoter. High-quality plasmid DNA 
was required for luciferase assays therefore large-scale plasmid preparations were performed 
for each construct. 
Table 6.6. Primers used to generate PGM1 promoter deletion constructs 
Primer name Sequence (5’-3’) Position Size of Fragment 
PGM1F587 5’ AGGCTAGCAAATCATGGGAAGAGAGCC 3’ -587 to -571 688 bp 
PGM1F135 5’AGGCTAGCGTTCTTACCCCAACCTCTGC 3’ -135 to -116 336 bp 




Figure 6.1 Co-ordinates of promoter deletion constructs and the putative transcription 
factor binding sites in the -2 Kb to +101 bp region of the PGM1 promoter.  Seven putative 
E2F sites are shown and one hypoxia responsive element is shown in blue.   
 
6.2.20 Site-directed mutagenesis 
Putative transcription factor binding sites in the -1988/+101 and -135/+101 region of PGM1 
promoter were disrupted by site-directed mutagenesis. Specific primers were designed to 
mutate and incorporate a restriction enzyme site within the binding region of the 
transcription factors, HIF (in the hypoxia responsive element) and E2F to allow for 
identification of positive clones. Primer X (http://www.bioinformatics.org/primerx/) was used 
to design optimal primers and these are depicted in (Table 6.7) below. Primers were designed 
in such as not to introduce any additional sites verified using the MatInspector software 
programme (https://www.genomatix.de/). The melting temperature (Tm) for each primer was 
calculated to be >75°C using the following equation (obtained from the Stratagene 
QuikChange site-directed mutagenesis kit instruction manual):  
Tm = 81.5 + 0.41 (% GC) – 675/N - % mismatch 





Table 6.7 Mutagenic primers used to disrupt transcription factor binding site  




-156HREmut_F 5’ CTTTTTTCCACCCTGCCTCggaTCCTTGCCCTATGACCG 3’ pGL3pPGM1 
-1988/+101 
BamHI 
-156HREmut_R 5’ CCGGTCATAGGGCAAGGAtccGAGGCAGGGTGGAAAAAA 3’ 
+19HREmut_F 5’ CTTTCCCCTCCCGCCGGAtCcGCCAGGAGGTGGGCTGG 3’ pGL3pPGM1 
-135/+101 
BamHI 
+19HREmut_R 5’ CCAGCCCACCTCCTGGCgGaTCCGGCGGGAGGGGAAAG 3’ 
-95E2Famut_F 5’ CACTTAGGGGAGGAGTctCGaGCCTCTTTTTACAGTG 3’ pGL3pPGM1 
-135/+101 
Xho1 
-95E2Famut_F 5’ CACTGTAAAAAGAGGCtCGagACTCCTCCCCTAAGTG 3’ 
+34E2Fbmut_F 5’ CTGCCAGGAGGTGGGCgctaGCGGAGGGAGGGCCCTG 3’ pGL3pPGM1 
-135/+101 
NheI 
+34E2Fbmut_R 5’ CAGGGCCCTCCCTCCGCtagcGCCCACCTCCTGGCAG 3’ 
+80E2Fcmut_F 5’ CCCTGTCCCTTTAAGGAGGAGGGCtAgcCGCCGGCCTAGAG 3’ pGL3pPGM1 
-135/+101 
NheI 
+80E2Fcmut_R 5’CTCTAGGCCGGCGgcTaGCCCTCCTCCTTAAAGGGACAGGG 3’ 
mutated bases are indicated in lower case and the restriction enzyme sites are underlined. 
The position of the first base on the 5’end of the putative TF binding site in included in the 
primer name. 
 
The different PCR reactions were set up as follows: 50 ng of plasmid DNA was used as 
template, 125 ng each of forward and reverse primers, 10x PFU buffer and 5 U PFU DNA 
polymerase, 3µl of 25mM MgCl2 and 5% DMSO, and 0.2mM dNTPs in 50 µl total volume. 
However, due to difficulties in cloning the +19HRE and -95E2Fa mutants, a different reaction 
recipe was used in order to optimize product output with each respective primer. The PCR 
reaction set up in the following manner: 30 ng of the plasmid DNA template was used 
together with 1.5 µl each of the forward and reverse primers indicated in (Table 6.7), at a 
stock concentration of 2µM, 1 µl of 10 mM dNTPs, 5µl of 10x PFU buffer (Fermentas) 5U of 
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PFU DNA polymerase and 1.5mM of MgSO4 made up to 50µl in nuclease-free dH2O.PCR was 
performed using the following cycling conditions: 95⁰C for 30 seconds, followed by 18 cycles 
of 95⁰C for 30 seconds, 55⁰C for 1 minute, and 72⁰C for 6 minutes, followed by a final 
extension step of 72⁰C for 20 minutes with an exception of the +19HREmut and -99E2Famut 
where the annealing temperature was increased to 61⁰C instead of 55⁰C. Following PCR 
amplification, 10 U DpnI (Promega) was added to the reaction mix and digestion carried out 
at 37⁰C for 90 minutes, before transformation into highly competent JM109 cells (Promega). 
Restriction digestion analysis was used to identify clones carrying the mutation. 
 
6.2.21 Chromatin immunoprecitation (ChIP) 
In order to determine whether specific transcription factors bind directly to the PGM1 
5’regulatory region ChIP assays were performed. Cells were grown till were about 90 % 
confluent in 2 x 150 mm culture dishes or 5 x 10 cm dishes, a fraction of cells were treated 
with hypoxia mimicking agent (nickel sulphate (II)) for experiments involving hypoxia 
responsive elements. When cells were at the correct confluency, 1 % formaldehyde was 
added and cells were incubated for 10 min at room temperature with shaking to cross-link 
the protein-DNA complexes. Then 0.125 M Glycine, pH 2.5 was added for 5 min to neutralise 
the reaction. Cells were then quickly rinsed twice in ice-cold 1X PBS and scraped into 1 ml of 
PBS, samples of the same experimental conditions were pooled together. The cell suspension 
was then spun down at 3000 rpm for 2 minutes at 4°C and the cell pellets re-suspended in 
300 µl lysis buffer and placed on ice for 10 min. The released chromatin from lysed cells was 
sheared using a sonicator to lengths of between 400 and 1000 bp on ice and the cell debris 
removed by centrifugation at 13000 rpm for 10 minutes. 20 µl of chromatin was kept and 
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diluted in 100 µl dilution buffer and stored at -20°C. The remainder of the chromatin was also 
diluted 1:10 in dilution buffer. Beads were prepared by blocking in 100 mg/ml salmon sperm DNA and 
5% BSA overnight at 4°C with rotation. The chromatin was then pre-cleared using protein-A agarose 
beads (Merck, NJ, USA) for 2 hr, then incubated with 2 mg antibody a-DP1 (K-20, sc-610, Santa Cruz 
Biotechnology); HIF 1-α (sc-13515, Santa Cruz Biotechnology), or no antibody negative control) at 4⁰C 
overnight with rotation. Protein-A agarose beads were added for another 2hr at 4⁰C, and immuno-
complexes bound by the beads recovered by centrifugation and washed twice sequentially in TSE I 
buffer, TSE II, Buffer III  and TE, pH 7.4. Bound chromatin was eluted using elution buffer (1% SDS, 0.1 
M NaHCO3) at room temperature for 10 minutes, and the input and eluted samples heated at 65⁰C 
overnight to reverse the cross-links from formaldehyde treatment. DNA was purified using the Wizard 
SV gel and PCR Clean-up System (Promega) and used for real-time PCR, using primers designed to 
span the E2F and HIF binding sites Primers 1, 2 and 3 and 2 respectively (Figure 6.8). Then PCR products 
were electrophoresed on 2% agarose gel and visualized. 
Table 6.8. Primers used for ChIP assays  





PGM1F-Primer-1 5' GTTGACCTTGCTATCCCCCG 3' -784 to -765 60 
205 BP 
PGM1R-Primer-1 5' CATGATTTGCCCCGCTGTGAC 3' -600 to -579 60 
PGM1F-Primer 2 5'TCTGACCCTCCCAACAGGT 3' -257 to -238 60 
180 bp 
PGM1R-Primer 2 5'TGAAAAAGAGGCCCGCAACT 3' -97 t0 -77 60 
PGM1F-Primer 3 5' CACTTAGAGGAGGAGTTGCGG 3' -110 to -90 60 
187  BP 






6.3.1 Tissue culture solutions 
Cell-freezing media 
70 % DMEM, 20 % Fetal Calf Serum and 10 % DMSO 
10 X PBS 
40 g NaCl, 1 g KCl, 5.75 g Na2HPO4.7H2O, 1 g KH2PO4, make up to 500 ml with dH2O 
MTT (5 mg/ml) 
100 mg MTT, 20 ml 1 X PBS, Vortex and incubate at 37°C for 15 min, Filter through a 0.2 µm 
filter, Wrap in foil and store at 4°C for up to one month 
Solubilisation Reagent  
25 g SLS, make up to 250 ml with dH2O then adding 76.6 µl conc. HCl 
 
 6.3.2 RNA solutions 
10 X MOPS Buffer 
0.2 M MOPS, 0.05 M Sodium Acetate and 0.01 M EDTA 
RNA Loading Buffer 
0.72 ml Formamide, 0.16 ml 10 X MOPS Buffer, 0.26 ml 37 % Formaldehyde, 0.18 ml dH2O, 




1.5 % agarose gel with formaldehyde 
0.75 g Agarose, 50 ml 1 X MOPS, 2.7 ml 37 % Formaldehyde and 2.5 µl Ethidium Bromide 
 
6.3.2 Protein solutions 
RIPA Buffer 
150 mM Sodium Chloride, 1 % Triton X-100, 1 % Sodium Deoxycholate, 0.1 % SDS and 10 
mM Tris-Cl, pH 7.4 
Resolving gel buffer 
36.2 g Tris, 0.8 g SDS, Dissolve in 150 ml dH2O, pH to 8.9 with 1 N HCL or 1 N NaOH and 
make up to 200 ml with dH2O. Stored at 4°C. 
Stacking Gel Buffer 
5.9 g Tris, 0.4 g SDS, Dissolve in 70 ml dH2O, pH to 6.8 with 1 N HCL or 1 N NaOH and make 
up to 100 ml with dH2O. Stored at 4°C. 
10x Running buffer 
30.2 g Tris, 144 g Glycine, 10 g SDS, make up to 1 L with dH2O  
1x Running buffer 
100 ml of 10x running buffer 900 ml of dH2O 
10x Transfer Buffer 
144 g Glycine 38 g Tris, make up to 1 L with dH2O  
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1x Transfer Buffer 
100 ml 10x transfer buffer (in this order) 700 ml dH2O, 200 ml methanol/isopropanol 
10x Tris Buffered Saline (TBS) 
60.5 g Tris, 87.6 g NaCl, dissolve in 700 ml dH2O, pH to 7.5 with 1 N HCL or 1 N NaOH and 
make up to 1 L with dH2O. 
1x TBST 
100 ml 10x TBS, 900 ml dH2O and 1 ml Tween 20 
4 X Laemmli Loading Dye 
250 mM Tris-Cl, pH 6.8 6 % SDS, 0.005 % Bromophenol Blue, 40 % Glycerol and 10 % β-
mercaptoethanol 
Rapid Coomassie Staining Solution 
0.024 % Coomassie Brilliant Blue, 10 % Acetic Acid and 90 % dH2O 
Destain 
10 % Acetic Acid 
6.3.3 DNA solutions 
TE Buffer 
10 mM Tris-Cl, pH 8.0 and 1 mM EDTA, pH 8.0 
10 X TBE 
108 g Tris, 55 g Boric Acid, 7.4 g EDTA up to 1 L with dH2O 
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6.3.5 Bacterial solutions 
Luria Broth (LB) medium 
10 g Tryptone, 5 g Yeast Extract, 10 g NaCl, 1 mM NaOH, make up to 1 L with dH2O 
LB agar 
Same as LB medium, but with 15 g Agar per litre 
Ampicillin (10 mg/ml) 
1 mg Ampicillin in 10 ml dH2O, filter-sterilise and store at -20°C 
X-gal (50 mg/ml) 
50 mg X-gal in 1 ml DMSO and store at -20°C in the dark 
IPTG (0.1 M) 
72 mg IPTG in 3 ml dH2O, filter-sterilise and store at 4°C 
6.3.6 ChIP Solutions 
Lysis buffer 
1% SDS, 5 mM EDTA, 50 mM Tris-Cl, pH 8.1 and  
1 X Complete Protease Inhibitor (Roche) 
Dilution buffer 
1% Triton X-100, 2mM EDTA, 150 mM NaCl, 20 mM Tris-Cl, pH 8.1 and  





0.1 % SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-Cl, pH 8.1  and  150 mM NaCl                                                                                                          
TSEII 
0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-Cl, pH 8.1, 500 mM NaCl      
Buffer III                                                                                                                                      
0.25 M LiCl, 1% NP-40, 1% Sodium Deoxycholate, 1mM EDTA, 10 mM Tris-Cl, pH 8.1 
Elution Buffer 
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